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ABSTRACT 
  The use of advanced imaging techniques has greatly improved orthopedic 
research and education. Histology of bone is a method of evaluating bone morphology, 
bony cells, and bone remodeling in two-dimensions, while micro-computed tomography 
(microCT) is a three-dimensional analysis of bone morphology. Combined, these 
methods assist in providing a comprehensive analysis of bone. In this dissertation, 
these techniques were utilized to answer questions currently outstanding in veterinary 
medicine: the effect of bisphosphonates on equine bone, and variation in murine tarsal 
anatomy.  
 Bisphosphonates are drugs that reduce osteoclast-mediated bone resorption and 
have recently been approved for the use in horses. Despite prolific clinical use, there 
has been little evidence of their effect on bone in horses. Therefore, the goal of these 
studies was to determine the impact of bisphosphonates on bone in normal, young 
horses. This was accomplished by evaluating bone biopsies taken before and 60 days 
after a single bisphosphonate administration. Biopsies were analyzed using microCT 
and histomorphometry. We found that the bisphosphonates studied have minimal to no 
effect on bone morphology and remodeling, and therefore conclude that these drugs do 
not negatively impact bone, and have no effect after 60 days.  
 Mice are the most commonly utilized animal model for orthopedic research, and 
knowledge of normal anatomy is critical to identify pathologies secondary to disease. 
We found conflicting evidence regarding the tarsal anatomy in the mouse. While normal 
tarsal variation exists in other species, this has not been documented in the mouse.  
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Therefore, the purpose of this study was to characterize the tarsal anatomy of the 
mouse. MicroCT data from muroid tarsi were collected, and representative tarsi were 
evaluated by histology. Fusion of the central and tarsal bone III was present in all 
laboratory mice evaluated, but was not present in the laboratory rat or wild white-footed 
mouse. This fusion was confirmed via histology; however, hyaline cartilage was present, 
surrounded by mature trabecular bone indicating a joint remnant despite the fused state 
of the bones. We conclude that in certain laboratory mouse strains, the central and 
tarsal bone III are fused into a single bone. 
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CHAPTER 1. 
 INTRODUCTION 
 
1.1 Review of Bone Biology 
 1.1.1 General Bone Anatomy 
 The normal human skeleton consists of 213 bones, which can be characterized 
based on shape and development (Clarke, 2008). These bones articulate together to 
provide a variety of functions to the body: structure and support to permit movement, 
storage of calcium and phosphate to maintain mineral homeostasis, and protection of 
internal organs and tissues (Weiner et al., 1999). General bone categories based on 
shape include long bones (e.g., femora, radii, and metacarpals), short bones (e.g., 
carpal and tarsal bones), flat bones (e.g., calvaria and ribs), and irregular bones (e.g., 
vertebrae) (Clarke, 2008). Long bones are longer than they are wide, comprised of a 
long, hollow shaft called the diaphysis, a rounded end proximal and distal to the growth 
plates called the epiphyses, and the area comprised of the growth plate between the 
diaphysis and epiphysis called metaphyses (Clarke, 2008). Contained within the 
diaphysis is a cavity called the medullary canal (Gray, 1918). Bone marrow is located 
within the bone medullary canal, and stores important hematopoietic and mesenchymal 
stem cells (Gurkan and Akkus, 2008). Short bones are as long as they are wide, and 
are composed of an outer cortical bone layer, with an inner trabecular bone center 
(Clarke, 2008). Flat bones are broad and thin, while irregular bones do not fit into the 
other categories and usually have unproportioned dimensions. However, they both 
contain an inner trabecular layer between dense cortical bone layers on either side 
(Gray and Goss, 1878, Rho et al., 1998).  
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 Bone is an organ, comprised of a hierarchical network of mineralized collagen 
fibrils, carbonated apatite crystals, and water (Weiner and Wagner, 1998). There are 
two types of bone based on gross morphology of the tissue: cortical and trabecular. 
Cortical bone, or compact bone, is dense and solid, providing strength and structure to 
bones by surrounding the medullary cavities (Clarke, 2008). Cortical bone is arranged in 
osteons, which are comprised of cylindrical rings of collagen fibers called lamellae, and 
contain a central canal that houses a neurovascular bundle (McGavin and Zachary, 
2006). Trabecular bone, or cancellous bone, is made up of hemi-osteons and are 
arranged in inter-connecting rods and plates, called trabeculae. This arrangement is 
directly related to the direction of stress placed on the particular bone.  
  The 3 main bone cells are osteoblasts, osteocytes, and osteoclasts (Raggatt and 
Partridge, 2010). Osteoblasts are derived from pluripotent mesenchymal stem cells, and 
are the bone-forming cells that synthesize the organic matrix and promote 
mineralization. Osteocytes are osteoblasts that become encapsulated within lacunae in 
newly-formed bone. Osteocytes have long processes that extend through small tunnels 
throughout the bone extracellular matrix. These small tunnels, or canaliculi, permit 
communication between osteocytes, as well as the bone surface (Raggatt and 
Partridge, 2010). Osteoclasts are macrophage polykaryons, formed through the 
differentiation of monocyte precursor cells, that degrades bone matrix by secreting 
enzymes and acid (Boyle et al., 2003).  
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 1.1.2 Bone Development 
 There are two classifications of bone development: endochondral and 
intramembranous ossification. Endochondral ossification is the process where bone 
replaces pre-existing cartilaginous anlagen (Olsen et al., 2000). The cartilaginous 
templates are formed during embryogenesis when mesenchymal cells condense and 
differentiate into chondrocytes (Erlebacher et al., 1995). After formation, chondrocytes 
within the anlagen proliferate and expand, producing cartilage matrix. Centrally-located 
chondrocytes mature into hypertrophic chondrocytes, creating a sequence of events 
that triggers specific factors to induce angiogenesis. During angiogenesis, osteoblasts, 
osteoclasts, and hematopoietic cells are brought into the location, allowing for 
mineralization to occur and creating primary ossification centers (Olsen et al., 2000). 
Endochondral ossification accounts for the formation of most of the skeleton, including 
the appendicular and axial skeleton (Ortega et al., 2004).  
Intramembranous ossification is the process by which mesenchymal cells 
differentiate directly into osteoblast cells, which produce bone directly without a 
cartilaginous precursor. Briefly, ossification begins with a thin layer of mesenchymal 
cells. As these cells become highly vascularized, they differentiate into isolated 
osteoblasts, which begin to secrete osteoid. This osteoid matrix will become mineralized 
by the end of the embryonic period, forming the beginning of the osteon (Cooper et al., 
2006). Flat bones of the skull and addition of new bone along the surfaces of long 
bones form through this process (Erlebacher et al., 1995).  
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 1.1.3 Bone Remodeling 
 Bones undergo normal remodeling in order to maintain structure and integrity, 
repair damage in response to external and internal forces, and maintain homeostasis of 
minerals within the body. Overall, there are five phases of bone remodeling: activation, 
resorption, reversal, formation, and termination (Raggatt and Partridge, 2010). 
However, the completion of these events may vary greatly due to pathology or 
pharmacological treatments (Eriksen, 2010). During the activation phase, signals to 
initiate the remodeling process are detected by osteocytes (Bonewald, 2007), which can 
be due to structural damage or hormonal changes (Raggatt and Partridge, 2010), such 
as changes in estrogen or PTH (Eriksen, 2010). Osteocytes play an important role in 
detecting structural stresses and translating them into bone remodeling activation 
signals (Aarden et al., 1994). Osteocytes secrete transforming growth factor β (TGF- β) 
under normal conditions, which inhibits osteoclastogenesis and slows down overall 
remodeling rates; however, when bone is under stress, osteocytes undergo apoptosis 
which increases osteoclastogenesis (Aguirre et al., 2006). The resorption phase follows 
activation, where osteoblasts respond to the signals produced by the osteocytes, and 
recruit osteoclast precursors to the area of remodeling activity. Additionally, osteoblasts 
produce a chemoattractant that recruits osteoclast precursors and receptor activators of 
NF-!B ligand (RANKL), which promotes osteoclastogenesis (Li et al., 2007). 
Osteoblasts also secrete matrix metalloproteinases (MMPs) that break down the lining 
of the bone surface and expose adhesion sites necessary for osteoclast attachment 
(Raggatt and Partridge, 2010). Osteoclasts attach themselves to the bone matrix, and 
rearrange their cytoskeleton so that a dense, actin structure forms a tight seal along the 
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edges of the osteoclast (Lakkakorpi et al., 1989). These edges enlarge and form a 
ruffled border (Stenbeck, 2002), completing the seal, and allowing the osteoclast to 
create a micro-environment within the sealed area under the osteoclast, which is critical 
in bone resorption (Baron, 1989). Once attached, osteoclasts create an acidic 
microenvironment by use of hydrogen pumps. Together with other enzymes, this 
degrades the bone matrix beneath the osteoclast, creating a Howship’s lacuna 
(Teitelbaum, 2000). Following resorption, the reversal phase begins, where 
mononuclear cells of undetermined lineage prepare the bone surface for bone formation 
by removing collagen remnants and producing bone formation signals (Raggatt and 
Partridge, 2010). Factors that initiate the formation phase from reversal phase have not 
been fully identified, but include a coupling factor that promotes bone formation while 
inhibiting bone resorption (Martin and Sims, 2005). Mesenchymal stem cells or 
osteoblast progenitor cells are directed to the lacunae to differentiate and produce 
osteoid. After deposition, hydroxyapatite is incorporated into the newly formed osteoid, 
finalizing the bone formation (Raggatt and Partridge, 2010). Finally, the termination 
phase begins when the resorbed bone has been replaced, which is thought to be 
induced by a lack of sclerostin expression that was present during bone formation 
phases (Sapir-Koren and Livshits, 2014). The resting bone surface is reestablished, and 
continues in this state until the remodeling process begins again (Raggatt and 
Partridge, 2010). 
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 1.2 Overview of Bone Diseases 
 1.2.1 Diseases of Bone Development 
 Due to the complex nature of bone formation, it should follow that any slight 
disturbance in these coordinated events can result in skeletal pathologies. During 
endochondral bone development, there are numerous factors that control specific 
processes necessary for normal bone development. During chondrogenesis, Sox 
proteins (e.g., Sox9) are critical for differentiation of mesenchymal stem cells into 
chondrocytes (Akiyama et al., 2002), proliferation of chondrocytes in growth plates of 
long bones (Akiyama et al., 2004), and upregulation of gene expression responsible for 
producing critical components of cartilaginous matrix (Bi et al., 2001). Additionally, 
fibroblast growth factor receptor (FGFR) 3 is expressed in proliferating chondrocytes 
(Provot and Schipani, 2005). FGFR3 affects long bone development and specific 
mutations within it cause skeletal dysplasias including achondroplasia, 
hypochondroplasia, and thanotophoric dysplasia, which are all forms of short-limb 
dwarfism (Vajo et al., 2000, Ornitz and Marie, 2002). Bone morphogenetic proteins 
(BMPs) are vital to inducing cartilage and bone formation. During development, BMP 
signaling is critical during the formation of joints by stimulating cartilage formation, 
localizing the expression of joint molecular markers to the appropriate location, and 
causing apoptosis at the joint location to create the cavitation (Baur et al., 2000, Yi et 
al., 2000). Inhibition of BMP signals can result in brachypodism (Storm et al., 1994), 
where the appendicular skeleton is affected and characterized by shorter phalanges 
with irregular ossification patterns (Grüneberg and Lee, 1973). These abnormalities 
occur before the formation of the cartilage anlagen and, being an abnormality of the 
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blastemata, result in abnormal fusions of the carpal and tarsal bones (e.g., fusion of the 
navicular and tarsal bone III in the tarsus) (Grüneberg and Lee, 1973).  
  
 1.2.2 Diseases of Bone Remodeling 
 In order for bone to remain structurally sound and functional, there must be a 
balance of bone formation and resorption, resulting in minimal to no net changes in the 
amount of bone in a healthy, mature skeleton. However, this delicate balance can be 
disrupted by certain pathologies which can affect both bone forming and bone resorbing 
pathways. Osteoporosis is one of the most common forms of bone remodeling 
disorders, where there is an overall loss in bone mass, causing bone fragility (Feng and 
McDonald, 2011). Due to the broad nature of this disease, it is divided into primary and 
secondary types (Panel, 2001, Marcus and Bouxsein, 2008). Primary osteoporosis is 
caused by age-related events, such as decreased gonadal activity (Riggs et al., 1969), 
while secondary osteoporosis is a consequence of chronic medical conditions that result 
in bone loss, such as cancer, hyperparathyroidism, use of corticosteroids, renal failure 
and vitamin D deficiency (Moyad, 2003, Painter et al., 2006). Age-related osteoporosis 
occurs most commonly due to the lack of gonadal function (Riggs et al., 1969), where 
there is a decrease in estrogen or testosterone. This leads to increased bone resorption 
that exceeds normal bone formation, resulting in a net loss of bone. However, 
osteoporosis does occur in both men and women, and can occur before age-related 
hormonal changes (Riggs et al., 1969, Painter et al., 2006). Hypogonadism can occur in 
young women and men, such as during androgen deprivation therapy for prostate 
carcinoma (Mittan et al., 2002) or anorexia (Grinspoon et al., 2000). Aside from sex 
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hormone changes, there are multiple factors that lead to an increase in parathyroid 
hormone (PTH) levels, such as primary hyperparathyroidism (Painter et al., 2006) or a 
decrease in calcium resorption in the gastrointestinal tract (Feng and McDonald, 2011), 
that result in increased bone resorption rate. 
 Bone remodeling disease in humans, such as with osteoporosis, affects the 
entire skeleton and is a systemic change in bone mass. In some animal species, 
however, bone disorders exist that affect only specific bones and do not result in a net 
change in the rest of the skeleton. In the horse, navicular disease is a degenerative 
disease of the navicular (distal sesamoid) bone within the hoof, along with its associated 
soft tissue structures (i.e., deep digital flexor tendon, impar ligament, and navicular 
bursa). Navicular disease is characterized by excessive remodeling of the navicular 
bone and a loss of bone mass (Widmer et al., 2000). The etiopathogenesis of navicular 
disease is complex and multifactorial, potentially including biomechanical (Wright and 
Douglas, 1993), vascular (Colles and Hickman, 1977, Doige and Hoffer, 1983) and 
hereditary components (Bos et al., 1986). Vascular changes include arteriosclerosis and 
thrombosis of the supplying arteries of the navicular bone (Colles and Hickman, 1977), 
while biomechanical changes in the load applied to the navicular bone can lead to 
damage and increased remodeling in response to the increased load (Trotter, 2001). 
 
1.3 Bisphosphonate Treatments for Diseases of Bone Remodeling  
 Management of bone disease, including osteoporosis, was advanced greatly by 
the use of bisphosphonate drugs in the late 1960s (Russell, 2011). Bisphosphonates 
(BPs) are a chemically stable form of inorganic pyrophosphate, which gives BPs a 
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strong specific affinity for calcium, and are composed of two phosphonate groups. BPs 
are separated into two classes based on their chemical structure: nitrogen-containing 
BPs (e.g., zoledronate, alendronate, and ibandronate) and non-nitrogen containing BPs 
(e.g., clodronate, tiludronate, and etidronate) (Russell et al., 1999). Differences in 
individual bisphosphonate drugs within each class depend on the compound attached to 
the functional, or R-, group (Reszka and Rodan, 2003). Both classes, however, inhibit 
osteoclast-mediated bone loss by decreasing osteoclast activity. Nitrogen-containing 
BPs are more potent in reducing osteoclast-mediated bone loss than non-nitrogen-
containing BPs, and changes in the functional group can also lead to different 
physiochemical and pharmacologic modifications. Non-nitrogen containing BPs have 
been shown to affect osteoclasts by disrupting intracellular metabolism through 
methylene-containing analogs of adenosine triphosphate (ATP) (Frith et al., 2001). This 
converts the BP into a toxic metabolite within the cell, and accumulation of this 
metabolite inhibits the mitochondrial adenine nucleotide translocase, resulting in the 
loss of the mitochondrial membrane potential (Lehenkari et al., 2002). These events 
lead to apoptosis of the osteoclast, ultimately inhibiting bone resorption (Reszka and 
Rodan, 2003). Nitrogen-containing BPs inhibit osteoclast activity by disrupting farnesyl 
diphosphate synthase (van Beek et al., 1999, Fisher et al., 2000), an enzyme in the 
mevalonate pathway, that stimulates isoprenylation, which is important in regulating 
osteoclast morphology, cytoskeletal arrangement, vesicular trafficking, and membrane 
ruffling (Zhang et al., 1995, Chellaiah et al., 2000). There appears to be a dose-
dependent response of nitrogen-containing BPs, where small concentrations inhibit 
osteoclast functions necessary for bone resorption, and high concentrations lead to 
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osteoclast apoptosis (Halasy-Nagy et al., 2001). Therefore, nitrogen-containing BPs are 
exceptional inhibitors of bone resorption (Kimmel, 2007).  
 The pharmacokinetics of BPs depends on their classification (Licata, 2005). In 
general, BPs are polar compounds, making them poorly, yet rapidly absorbed after 
being ingested (Lin, 1996). BPs generally have <2% bioavailability (Yakatan et al., 
1982), and have low plasma protein binding of approximately 30% (Pentikäinen et al., 
1989). The peak serum concentration is obtained quickly following a single oral dose, 
within approximately 30 minutes (Laitinen et al., 2000). Most BPs are not metabolized, 
and are therefore excreted unchanged (Pentikäinen et al., 1989). BPs have a half-life of 
approximately two hours, with bone uptake and renal clearance accounting for the rapid 
clearance from plasma (Cocquyt et al., 1999). BPs have a high affinity for exposed 
hydroxyapatite, which occurs when bone surfaces are preparing for or currently 
undergoing bone resorption (Sato et al., 1991, Lin, 1996), which allows BPs to be taken 
up and stored in bone mineral surfaces (Russell et al., 1999), accounting for 
approximately 50-60% of the absorbed dose (Licata, 2005). The amount of BP released 
from bone depends on the rate of the remodeling process (Gatti and Adami, 1999), as 
the BPs are released when the bone matrix is dissolved during the remodeling process.  
 In addition to inhibiting bone resorption, the non-nitrogen containing BPs 
clodronate and etidronate have been shown to produce analgesic effects by entering 
neurons through the SLC20/34, and inhibiting glutamate and/or ATP transporters 
(Shima et al., 2016). Taken together, bisphosphonates are used in the treatment of 
numerous bone diseases in humans, including osteoporosis, Paget’s disease, 
hypercalcemia of malignancies associate with myeloma and bone metastases, and 
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osteogenesis imperfecta (Russell, 2011), and recently for horses with navicular disease 
(Denoix et al., 2003, Whitfield et al., 2016) and other skeletal pathologies [e.g., 
osteoarticular disease (Coudry et al., 2007, Gough et al., 2010, Soto and Barbará, 
2014) in veterinary medicine.  
 
1.4 Assessments of Bone Health 
 1.4.1 Non-Invasive Assessments 
 In many bone diseases, diagnostic and assessment of disease progression are 
critical factors in minimizing negative outcomes for a patient. Historically, obtaining a 
bone biopsy was considered the most powerful and informative evaluation technique for 
bone assessment (Malluche et al., 1999). However, this method is invasive, and may 
not be desirable in a diseased patient. In a human clinical setting, obtaining 
informational data, while remaining as non-invasive as possible, is critical in patient care 
and disease management. Radiographic imaging has long been the gold standard for 
evaluating a variety of pathologies, including bone disease (van de Heijde, 2000). 
Radiographs are obtained by photons generated and emitted from a cathode tube that 
is collimated to a specific region of interest. As the photons pass through the body, the 
photons will be attenuated by tissue according to density, providing levels of exposure 
to film for imaging (Drake et al., 2014). Although radiographs are routinely used in 
numerous fields of medicine, they can only detect bone losses of greater than 40-50%, 
and are therefore not sensitive enough to monitor progression of disease or treatment 
(Moyad, 2003).  
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For diseases that lead to bone loss, the bone mineral density (BMD) 
measurement is the primary diagnostic test and is the gold standard and best predictor 
of fracture risk (Hui et al., 1989, Moyad, 2003). BMD produces a relative, overall T-
score that describes the number of standard deviations a patient’s density is from a 
group of similarly matched young, normal individuals. There are numerous ways to 
obtain BMD, including ultrasound, computerized tomography (Yakatan et al.), dual-
energy X-ray absorptiometry (DEXA) and radiographs (Moyad, 2003). Ultrasound is the 
use of high frequency acoustic waves produced by piezoelectric material that passes 
through tissues without the use of ionizing radiation. As the waves pass, they bounce 
back based on tissue properties, are received back through the piezoelectric material, 
and are interpreted by a computer, producing a real-time image (Drake et al., 2014). 
Because it does not use radiation, ultrasound is a popular imaging modality, specifically 
in young adults and children, for monitoring bone disease (Siffert and Kaufman, 2007). 
In addition to providing information about bone density, ultrasound can also provide 
information about bone quality, such as elasticity and microarchitecture (Prins et al., 
1997). However, there is little information about overall sensitivity and accuracy of serial 
measurements (Moyad, 2003). CT scans produce an image by passing a mobile X-ray 
tube around the body, creating a series of serially-sectioned two-dimensional images of 
the body (Drake et al., 2014). When these images are stacked together, a three-
dimensional (3D) view is produced. CT is capable of producing extremely high-
resolution images, but will emit increased radiation to do so. Therefore, although CT has 
the highest sensitivity in detecting changes in bone density and trabecular and cortical 
bone morphology, it is expensive, requires specialized software for analyses, and can 
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produce large amounts of radiation, making it challenging to obtain multiple scans over 
an extended period of time (Moyad, 2003). DEXA is a dual energy source of X-ray that 
has much higher sensitivity and accuracy, while also decreasing radiation exposure 
compared to other forms of radiation imaging. In addition, DEXA is inexpensive 
compared to other imaging modalities, making it an ideal technology for serial 
measurements, and is the current gold standard for obtaining BMD measurements in a 
clinical setting (Moyad, 2003).  
In the veterinary clinical setting, the basic radiograph is still one of the most 
common diagnostic techniques utilized, but can be combined with additional imaging 
modalities, such as nuclear scintigraphy. Nuclear scintigraphy is a radionuclide bone 
imaging technique, where the uptake of radiopharmaceuticals, typically technetium-
99m-labeled diphosphonates for bone, quickly deposits into the bone matrix (McKillop 
and Fogelman, 1984). Areas of increased uptake indicate areas of abnormal remodeling 
and mineralization. Nuclear scintigraphy is highly sensitive, making it possible to detect 
the earliest stages of bone disease; however, due to poor resolution, the specificity is 
generally moderate to low (Weller et al., 2001), and limits its use in bone imaging in 
both human and veterinary medicine. In systemic abnormal bone remodeling, specificity 
is not as important in diagnosis; however, in localized disease where small tissues are 
involved, such as navicular disease, specificity is crucial for accurate diagnosis and 
characterization. When combined with other imaging, such as radiography, nuclear 
scintigraphy is a more useful tool in diagnosing and monitoring abnormal bone 
remodeling (Weller et al., 2001), such as with navicular disease (Dyson, 2002) or 
osteochondral diseases (Kawcak et al., 2000). 
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 1.4.2 Invasive Assessments 
  1.4.2.1 Histology 
 In research settings, there is less emphasis on patient comfort and longevity, and 
more emphasis on obtaining the most sensitive and accurate data possible, allowing for 
more invasive data collection methods. In this case, animal models of human disease 
are typically used, or animal models of animal disease in veterinary research. The more 
invasive technique of obtaining bone biopsies remains the gold standard for 
quantification of bone remodeling (Allen, 2003). Though obtaining bone biopsies is more 
invasive than most clinical settings prefer, research settings benefit greatly from 
numerous parameters available for direct evaluation through the use of histology. 
Histology is the process of embedding bone (or any other tissue) samples into a 
transparent material and taking thin, serial sections for examination under a microscope 
(Recker et al., 2011). Histomorphometry is the measurement of form and structure of a 
histologic tissue sample, permitting quantitative analysis of the structure (Duque and 
Watanabe, 2011). Previously, bone had to be de-mineralized by strong mineral or 
organic acids or acidic buffers, which would rapidly decalcify bone, so thin sections of 
bone could be sectioned for viewing (Recker et al., 2011). However, these agents were 
known to cause collagen fiber distortions and change the affinity of the tissue structure, 
weakening the staining outcomes; therefore, chelating agents, such as ethylenediamine 
tetraacetic acid (EDTA), have since replaced previous agents, as they do not have 
these negative secondary outcomes (Kiviranta et al., 1980). In the 1950s, however, a 
new method of embedding un-decalcified bone into plastic greatly improved bone 
research by allowing visualization and assessment of bone with its mineral components 
	15	
(Frost et al., 1960). By preserving calcium in bone samples, a new technique of 
detecting newly-formed bone and mineralization, called fluorochrome labeling, was 
possible. Fluorochrome labeling uses injectable, calcium-binding tetracycline agents to 
directly measure bone remodeling dynamics in vivo over time (Frost, 1969). 
Tetracycline agents are able to make a complex with calcium that is deposited in areas 
of bone mineralization, and becomes permanently fixed within the mineralized matrix 
unless disturbed by subsequent remodeling processes (Frost et al., 1961). This 
deposition of tetracycline creates a brightly-lit area along the bone surface when 
exposed to ultra-violet light, indicating areas of remodeling and mineralization (Perrin, 
1965). Fluorochrome bone labeling has since been greatly advanced, with new methods 
of labeling bone with up to 7 distinct labels analyzed by specialized spectral image 
acquisition software, allowing numerous time points for analyses with decreased tissue 
collection requirements (Pautke et al., 2005). In addition to bone remodeling, data on 
bone structure and bony cells are analyzed. Various staining solutions are utilized to 
highlight certain features, such as tartrate-resistant acidic phosphatase (TRAP) staining 
using an enzyme-histochemistry protocol for specific staining of osteoclasts and alkaline 
phosphatase (ALP) staining for osteoblasts. There are some limitations of 
histomorphometry, however. Overall, slicing sections of the sample is inherently 
destructive, and an analysis on a small portion of the skeleton is difficult to generalize to 
the rest of the skeleton. Additionally, histomorphometry is a 2D evaluation that 
determines 3D parameters through the mathematical discipline of stereology, which 
interpolates 3D measurements from 2D measurements using mathematical theorems. 
However, despite being an estimation of 3D parameters, there is minimal and 
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acceptable error when applied to trabecular bone from ilium samples (Parfitt et al., 
1987, Dempster et al., 2013). Finally, histomorphometry is not the best assessment for 
bone mass, due to the 2D nature of the slice, as well as the small relative size of the 
section (Duque and Watanabe, 2011).  
   
  1.4.2.2 Micro-Computed Tomography 
 To overcome some limitations associated with histomorphometric analyses, 
evaluations are combined with micro-computed tomography (microCT). MicroCT is a 
high-resolution form of CT, and is an imaging modality to assess trabecular and cortical 
bone morphology with resolutions between 0.5 – 50 μm. MicroCT provides direct 
measurements of 3D bone morphology of entire biopsy samples, while providing 
excellent specificity and sensitivity using standardized parameters (Bouxsein et al., 
2010). The high resolution increases radiation exposure to the sample; however, in 
research settings the specimens are usually taken from animals that are euthanized or 
biopsies are collected from live animals. Combined with histomorphometry, a 
comprehensive analysis is possible, obtaining information about bony cellular 
morphology, bone remodeling dynamics and bone structure (Duque and Watanabe, 
2011). 
  
 1.4.3 Use of Imaging in Education and Research 
 With the advancements in medical imaging, anatomical education in both human 
and veterinary medicine have both benefited and incorporated many data in the medical 
anatomy curriculum. An in-depth understanding of anatomical structures and 3D 
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relationships is critical in medical training. High resolution images are obtained and can 
be combined to provide visual and technical experience for surgeons in training (Wiet et 
al., 2005). For example, high-resolution magnetic resonance imaging (MRI) and 
microCT data can be combined to visualize both soft and hard tissues within a sample, 
providing a visual and haptic display for a simulation of temporal bone dissection (Wiet 
et al., 2005). In addition to computerized visualizations, 3D printing is utilized in 
classrooms to provide additional understanding of anatomical structures (McMenamin et 
al., 2014). This is especially useful for biological structures or systems that are difficult 
to observe or manipulate in cadavers (AbouHashem et al., 2015). In addition to 
education, research relies on accurate representation of normal anatomical features, 
and benefit from high-resolution, 3D images of biological structures (Duce et al., 2010). 
Variation in reported anatomy greatly limits the potential for comparative anatomy 
between studies (Duce et al., 2010), and can limit the understanding of normal and 
pathological anatomical characteristics (El-Menyar et al., 2017).  
 
1.5 Animal Models of Orthopedic Disease 
 1.5.1 Selection of Animal Models 
 Animal models play a crucial role in the understanding, prevention and treatment 
of orthopedic disease for both human and veterinary medicine. However, there are 
important distinctions between human and animal bone that have implications for 
research outcomes (Aerssens et al., 1998). For example, bone repair rates differ 
between large and small species, and are inversely related to the species’ position on 
the phylogenetic scale, meaning rats have a higher rate of bone regeneration than 
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humans (Martini et al., 2001). In terms of bone composition, human bone is best 
represented by canine bone (Aerssens et al., 1998), but canine bone can withstand 
significantly higher compression strain than human bone (Kuhn et al., 1989). The use of 
quadrupeds as an animal model for human health has been questioned, especially in 
relation to differential loading secondary to bipedalism in humans. However, certain 
animal models can be selected based on specific criteria pertinent to the study (e.g., 
use of sheep in spine research due to similarities to humans in long axis loading (Smit, 
2002)). 
The type of animal model selected for research also depends on the aim of the 
study. When determining the pathogenesis and pathophysiology of a particular disease, 
smaller animals offer quick and cost-effective models than do larger animals. Small 
animal models also offer quick screenings of therapeutic interventions and drug safety. 
Large animal models, however, offer similar body size to humans and therefore can 
make therapeutic or surgical interventions more translatable to humans (Kuyinu et al., 
2016). Thus, researchers must carefully evaluate the goals and anticipated outcomes of 
a study when determining the appropriate animal model. When evaluating animal 
diseases in veterinary medicine, researchers often have the benefit of using the specific 
animal of interest, eliminating the need for a translatable model. However, the 
disadvantages of the specific species have to be accounted for, including expense and 
the impact of ethical limitations imposed for use of companion animal species. 
Therefore, there is usually smaller sample sizes available for research utilizing large 
animal models. 
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 1.5.2 Small Animal Models 
 The most common small animal orthopedic models include the rat, mouse, 
guinea pig and rabbit (Aerssens et al., 1998, Kuyinu et al., 2016). Small animal models 
have numerous advantages, including ease of handling, economical housing costs, 
short breeding cycles and well known genetics (Histing et al., 2011). For mice, a known 
genome make them the perfect model for utilizing genetic manipulations to study 
molecular mechanisms. Due to an increase in use of rodents in research, specifically 
mice, much information is known about their physiology, and many experimental 
protocols and kits are designed for this species. This makes their use more standard 
and widely available for additional research, and make them more favorable than a 
large animal model that does not have the same available data (Histing et al., 2011).  
  
 1.5.3 Large Animal Models 
 Non-human primates offer valuable information to human medicine due to their 
very similar physiological and behavioral characteristics (Kuyinu et al., 2016). Although 
non-human primates are the most relevant in terms of mimicking human disease, they 
are extremely expensive and are associated with ethical concerns, in addition to the 
possible spread of infectious disease, making them a difficult option for many 
researchers (Reinwald and Burr, 2008). Therefore, cost-effective alternatives to non-
human primates, such as ungulate and canine species, are practical, large animal 
model substitutes. Although more expensive in terms of management, large animal 
models are a necessity in certain research, such as osteoporosis and osteoarthritis 
research, due to their longer lifespan, similarities in osteonal remodeling and naturally-
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occurring disease (Reinwald and Burr, 2008). Additionally, it is extremely important that 
the animal model develop the desired disease in a similar pathway, such as a loss of 
estrogen in an osteoporosis model, so that therapeutic interventions behave similarly in 
both the animal model and human. Dogs have long been considered the ideal 
alternative to the non-human primate, and have been one of the most studied large 
animal models for orthopedic research (Martini et al., 2001). However, the use of dogs 
poses a similar ethical concern as do non-human primates due to their companion 
status (Rollin, 2006), and the use of dogs has since decreased in research settings. 
Pigs have physiological similarities to humans, including sequential skeletal phases of 
development. Sheep are another alternative large animal model, and are being used 
more frequently in orthopedic research due to their ease of handling (Martini et al., 
2001). Horses are mostly utilized in osteoarthritis research, as they have a similar risk to 
humans for developing naturally-occurring osteoarthritis secondary to trauma or as a 
result of age, as well as exercise-related osteochondral defects (McIlwraith et al., 2012). 
Additionally, they are large enough to use standard imaging modalities. All of these 
species are large and expensive, making management and handling more difficult than 
small animal models, which are important considerations when initiating research 
studies using these models (Gregory et al., 2012).  
 
1.6 Summary and Specific Aims 
 Overall, bone is a highly complex, active structure that provides organisms with 
essential protection and support. Orthopedic research has been greatly advanced by 
imaging modalities, allowing researchers to visualize and evaluate bone health, bone 
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diseases and therapeutic interventions for both human and veterinary medicine. 
Combining evaluation techniques, such as histology and microCT, can overcome the 
disadvantages of each technique, and provide comprehensive detail of bone 
morphology and cellular structure. In addition, advanced imaging techniques can be 
used to provide anatomy depictions for both research and education. Based on this, the 
following research has been performed to address currently unknown information in 
veterinary medicine regarding bone health in horses and muroid species, and is 
summarized in the following aims: 
  
Aim 1: Determine the effect of the bisphosphonates tiludronate on normal bone 
turnover, bone morphology and bony cells in skeletally immature horses via microCT 
and histomorphometry. 
 Summary: To test the effect of tiludronate on bone, biopsies from the tuber 
coxarum were taken from ten horses aged two - five years old. A baseline biopsy was 
collected at Day 0, and horses were then administered either tiludronate or saline. 
Horses were administered oxytetracycline as a fluorescent bone label at Day 47 and 57 
for evaluation of bone remodeling. A second biopsy was collected at Day 60 from the 
contralateral tuber coxarum. Samples were fixed and scanned by microCT for 
evaluation of trabecular bone morphology. The biopsies were then prepared for 
decalcified and un-decalcified histology for evaluation of bony cells, bone morphology 
and bone remodeling following standard techniques and nomenclature. This aim will 
establish if tiludronate affects normal bone structure and remodeling in skeletally 
immature horses. The hypothesis is that tiludronate will reduce osteoclast numbers and 
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function, resulting in increased bone volume and decreased bone remodeling in young 
horses. 
 
Aim 2: Determine the effect of clodronate on normal bone turnover, morphology and 
repair in skeletally immature horses via microCT and histomorphometry. 
 Summary: Aim 2 utilized the study design and techniques as outlined in Aim 1. In 
brief, biopsies were taken from nine horses aged two – four years old; a baseline biopsy 
(Day 0), a contralateral biopsy (Day 60), and a re-biopsy of the initial site (Day 60R), 
providing a biopsy after a bone defect. Clodronate or saline was administered 
immediately following Day 0 biopsy collection. Preparation and assessments were 
identical to Aim 1. Additionally, the Day 60R biopsy was scanned via microCT and then 
prepared for decalcified histology. This aim will first establish our equine model as an 
adequate model of bone repair. Subsequently, this aim will determine if clodronate 
impacts bone structure and repair in skeletally immature horses. The hypothesis is that 
clodronate will result in increased bone formation in an equine model of bone healing, 
as well as reduce osteoclast numbers and function, resulting in increased bone volume 
and decreased bone remodeling in young horses. 
  
Aim 3: Characterize the anatomy of the mouse tarsus and clarify the presence and 
number of bones within this region in normal laboratory mice. 
 Summary: Bony anatomy of the tarsi from two strains of commonly used 
laboratory mice (i.e., C57/Bl6 and BalbC) were evaluated for bony anatomy 
characteristics via microCT. This anatomy was compared to selected outgroups, 
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including the closely-related laboratory rat (Sprague Dawley®) and the more distantly 
related wild white-footed mouse (Peromyscus leucopus). Representative mouse tarsi 
were selected for routine decalcified histology preparation, where serial, sagittal 
sections were taken through the mid-tarsus. The hypothesis is that normal laboratory 
mice have a fusion of the central and tarsal bone III, which is not present in other 
outgroup species evaluated.  
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CHAPTER 2. 
INFLUENCE OF TILUDRONATE ON BONE CELLS, MORPHOLOGY 
AND REMODELING IN YOUNG HORSES1 
 
2.1 Introduction 
Tiludronate disodium (Tildren, Ceva Animal Health LLC, Lenexa, KS, USA) is a 
bisphosphonate drug that is licensed for use in horses to reduce lameness associated 
with navicular disease (Denoix et al., 2003, Whitfield et al., 2016). Tiludronate has a 
high affinity for bone (Henneman et al., 2008) and reduces osteoclastic activity (David et 
al., 1996), resulting in inhibition of bone resorption and subsequent uncoupling of the 
balanced remodeling process (Murakami et al., 1995, David et al., 1996, Kamm et al., 
2008). Tiludronate has been shown to have potential effectiveness to treat 
musculoskeletal conditions other than navicular disease, such as distal tarsal joint 
osteoarthritis (Gough et al., 2010), thoracic and lumbar vertebral arthritis (Coudry et al., 
2007) and dorsal metacarpal disease (Carpenter, 2012). However, these studies all 
report data on clinical outcomes (e.g., improvement in lameness), and not the effect on 
bone. Similarly, clinical studies have shown a reduction in lameness associated with 
navicular disease following tiludronate treatment (Denoix et al., 2003, Whitfield et al., 
2016). One barrier to the field is currently a lack of data regarding the direct impact on 
bone remodeling kinetics in horses. Only a single study has attempted to evaluate 
tiludronate’s direct impact on bone; however, it was unsuccessful (Delguste et al., 
2007). In addition, tiludronate has been administered to young horses as a treatment for 
dorsal metacarpal disease (Carpenter, 2012), despite their still having to undergo a 
																																																						
1 Parts of this chapter previously appeared as Mitchell, C.F. et al., Assessment of Tuber 
Coxae Bone Biopsy in the Standing Horse. Vet Surg (2017) DOI: 10.1111/vsu.12603. 
Reprinted by permission of John Wiley and Sons via RightsLink.  
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tremendous amount of bone remodeling as a part of normal bone growth (Müller et al., 
1998). Despite the potential impact of tiludronate on normal bone remodeling kinetics, a 
detailed study has not been performed to determine if tiludronate negatively affects 
normal bone remodeling in young horses.  
The gold standard for bone analyses are histomorphometry (Müller et al., 1998) 
and microCT (MacNeil and Boyd, 2007), both of which require bone biopsies. The tuber 
coxarum has been reported to be the easiest site for bone biopsy acquisition in the 
horse and is a region that was found to have consistently higher levels of tiludronate in 
comparison to other bones (Delguste et al., 2011). A recently published study by the 
authors has shown the tuber coxarum as a site to obtain reliable bony samples in a non-
terminal equine model that are consistent in size and of adequate quality to evaluate 
trabecular bone using both histomorphometry and microCT (Mitchell et al., 2017).  
Therefore, the aim of this study was to evaluate the effect of tiludronate on bony 
cells, bone morphology and remodeling in skeletally-immature, clinically healthy horses. 
This was accomplished by evaluating bone biopsies, obtained from the tuber coxarum 
using a previously published surgical technique (Mitchell et al., 2017), via microCT and 
histomorphometry. We hypothesized that tiludronate administration would result in 
increased bone volume, decreased osteoclast numbers and activity, and increased 
bone apposition when compared to control samples.  
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2.2 Materials and Methods 
Study Design 
The experimental protocol was approved by the Louisiana State University 
Institutional Animal Care and Use Committee (IACUC) (Protocol #14-069). Ten clinically 
healthy Thoroughbred horses (two - five years of age and weighing between 409 kg and 
570 kg) were obtained via donation to the Louisiana State University Equine Health 
Studies Program. Medical history of the horses was unknown at the time of donation; 
however, prior to enrollment in the current study, all horses underwent at least a two-
week isolation and washout period following donation. Horses were randomly assigned 
using a coin flip to either a treatment (n=5) or control group (n=5). The surgeon, who 
was not involved in subsequent analyses, was not masked to treatment groups. All 
personnel who took part in the data collection and analysis were masked to treatment 
groups.  
Bone biopsies were taken from each horse at Day 0 (baseline before treatment) 
and Day 60 (60 days post-treatment) (Figure 2.1). This time frame was determined by 
previous studies that showed a positive effect of tiludronate administration in horses 60 
days post initiation of treatment (Denoix et al., 2003, Coudry et al., 2007, Gough et al., 
2010). The right or left tuber coxarum was randomly selected, via coin flip, for the first 
biopsy (outlined below in “Surgical Procedure”). Immediately following the initial biopsy 
surgery (Day 0), each horse was administered tiludronate (1 mg/kg, diluted in 1L of 
0.9% saline, IV) or equal volumes of saline. The tiludronate solution was administered 
over 90 minutes using an IV fluid pump. The horses stood in the stocks during this 
infusion and were monitored for signs of colic. Sixty days later, the contralateral tuber 
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coxarum was biopsied in the same manner. Prior to the second biopsy, oxytetracycline 
(Vetrimycin 100, VetOne, Boise, ID, USA) was administered at Day 47 and Day 57 as a 
fluorochrome label to identify bone remodeling parameters. Biopsies were evaluated 
with microCT and histomorphometry for changes in bone morphology and remodeling 
rates, as outlined below under “MicroCT” and “Histology.”   
 
 
Figure 2.1 Tiludronate study design schematic of time line, outlining biopsy collection 
and treatment administration. Abbreviations: Contra., Contralateral; Ipsi., Ipsilateral. 
 
Study Horses 
Thoroughbred horses, as outlined above under “Study Design”, were included if 
they were free from outward musculoskeletal disease and clinically healthy, as 
assessed by a boarded veterinary surgeon (CFM) during a physical exam, and included 
seven geldings and three fillies with a mean age of 3.5 years (control age: (mean ± SD) 
3.4 ± 1.14 years; weight: 500.6 ± 44.8 kg; treated age: 3.6 ± 1.34 years). Sample sizes 
were influenced based on donation availability, and all eligible horses were considered. 
Additionally, if eligible horses became available during the course of data collection, 
they were evaluated and included in order to maximize sample size. Throughout the 
study, they were housed in individual stalls following the biopsies and then turned out in 
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groups in pastures. They were fed free choice hay and water, with grain being provided 
twice daily.  
In addition to the aforementioned horses, biopsies were also obtained from three 
additional horses euthanized for non-musculoskeletal related reasons at the Louisiana 
Disease and Diagnostic Laboratory (LADDL). These were samples of convenience, 
obtained at necropsy from horses not included in this study. These horses were aged 9 
months, 1 year, and 25 years, and were used to compare histopathological changes 
within the biopsies with age. The samples were obtained using the same surgical 
technique, as described below, but were not enrolled in the pharmacologic evaluations. 
 
Surgical Procedure & Treatment 
Horses were sedated with intravenous (IV) xylazine (Xylamed, Bimeda, 
Cambridge, ON Canada) (0.35 to 0.5 mg/kg). The surgical method has been previously 
published in detail (Mitchell et al., 2017). In short, the biopsy site was centered on the 
proximal palpable protuberance of the tuber coxarum. A rectangular region 
(approximately 10 cm X 10 cm) was clipped around the tuber coxarum and then 
aseptically prepared. Lidocaine (Lidocaine 2%, VetOne, Boise, ID, USA) was injected 
subcutaneously, deep to the proposed incision site in a vertical line, centered on the 
palpable tuber coxarum, extending 4 cm proximal and distal to that palpable point and 
then deeply, adjacent to the periosteum of the tuber coxarum. The horse was further 
sedated with detomidine hydrochloride (Dormosedan, Zoetis, Kalamazoo, MI, USA) (3 
to 5 mg IV) and butorphanol tartrate (Torbugesic, Fort Dodge, New York, NY, USA) (3 
to 5 mg IV) prior to making the skin incision (Mitchell et al., 2017). 
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A 6-8 cm, vertically oriented incision was made over the tuber coxarum (Figure 
2.2A), and dissected to expose the cranial, caudal, proximal and deep margins. The 
periosteum was incised with a #15 blade in a cranial to caudal direction on the lateral 
edge of the tuber coxarum, at least 1 cm distal to the proximal portion of the 
protuberance. An oscillating saw was used to transect the protuberance of the tuber 
coxarum, with the saw blade angled either parallel to the ground or slightly dorsally, 
depending upon the position of the limb and the horse’s pelvic anatomy. In order to limit 
thermal damage, the saw blade was continuously lavaged with saline. Depending upon 
the direction of the saw cut, the bone biopsy (Figure 2.2B) was either removed, or 
detached from soft tissue prior to removal. The excised section of bone representing the 
biopsy was at least 1 cm tall, with the width and length of the biopsy dependent on each 
horse’s pelvic anatomy. The goal was to obtain the largest biopsy possible without 
cutting into the iliac crest on the deep border of the tuber coxarum. If necessary, the 
horizontal cut was moved distally and the saw blade angled in a more proximal direction 
to produce a biopsy of suitable size. The surgery site was lavaged, and the 
subcutaneous tissue was sutured with 2-0 polyglactin 910 in a simple continuous 
pattern. The skin was sutured using 0 polypropylene in either a Ford interlocking or 
cruciate pattern. An aluminium based bandage spray (Aluspray, Neogen Corporation, 
Lexington, KY, USA) was applied to the surgery site and a lidocaine patch (Lidocaine 
Patch 5%, Qualitest, Huntsville, AL, USA)  was then applied over the incision (Mitchell et 
al., 2017).  
Following the initial biopsy (Day 0 to 1), horses were stalled for at least 24 hours 
and monitored every 2 hours over the first 24-hour period using a visual pain score  
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Figure 2.2 Bone biopsy from the tuber coxarum in a horse. A) The incision is centered 
over the palpable dorsal protuberance of the tuber coxarum. The excised piece of tuber 
coxarum is directly above the saw blade, with a small amount of connective tissue on its 
superficial edge. Cranial to the left of image, proximal to the top of image. B) Bone 
biopsy harvested. Cut surface facing up, resting on a 10.1 X 10.1 cm gauze square. 
MicroCT 
 
(Doherty and Valverde, 2006). After 24 hours, horses were returned to their respective 
pastures and checked daily for signs of lameness or incisional complications until suture 
removal at 14 days post biopsy. At Day 47 and 57 post biopsy, the horses were treated 
with 25 mg/kg of oxytetracycline administered slowly IV. Sixty days after the initial 
biopsy, the contralateral tuber coxarum was biopsied using the same surgical methods 
as described above. However, after surgery, horses were administered flunixin 
meglumine (Prevail, Bimeda, Cambridge, ON, Canada) (1.1 mg/kg IV) as an additional 
analgesic. Surgical aftercare was identical to above from post-surgery to 14 days later 
when the sutures were removed.  
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MicroCT 
Following biopsy, tuber coxae samples were dissected free from tissue and fixed 
in 10% non-buffered formalin for seven days, then transferred to and stored in 70% 
ethanol at 20˚C. Samples were placed in holders with 70% ethanol for scanning by 
microCT (Scanco model 40, Scanco Medical AG, Basserdorf, Switzerland). Biopsies 
were scanned at 55kV, 0.3-second integration time, with a 30 µm voxel size in plane 
and a 30 µm slice thickness. The region of interest was determined for trabecular bone. 
The proper threshold for image segmentation was tested, with the same threshold being 
used throughout the experiment. Trabecular bone was evaluated for bone volume (BV), 
total volume (TV), BV/TV, tissue mineral density, trabecular number (Tb.N), trabecular 
thickness (Tb.Th), trabecular spacing (Tb.Sp), connectivity density (Conn.D) and 
structural model index (SMI) based on established procedures and nomenclature 
(Bouxsein et al., 2010).  
 
Histology 
Following microCT evaluation, biopsies were prepared for histology. Day 0 
biopsies were prepared for decalcified histology, and Day 60 biopsies were prepared for 
undecalcified histology so visualization of fluorochrome labels was possible. Due to 
differences in preparation techniques between decalcified and undecalcified histology, 
and size of slides used for each, histological preparation of both sets of biopsies differed 
slightly. However, care was taken to ensure sections from each biopsy were taken in 
the same location and plane of section, regardless of preparation method. Day 0 
biopsies were decalcified with 10% ethylenediaminetetraacetic acid (EDTA) and 
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prepared for routine paraffin embedding. In order to fit on glass histological slides, Day 
0 biopsies were split in half and embedded separately. This resulted in 6 – 8, 4 µm thick 
sections per biopsy that were stained with hematoxylin and eosin (H&E). Day 60 
biopsies were prepared intact for undecalcified histology and two, 45-60 µm thick 
sections were produced. The first was stained with Stevenel’s Blue and Van Gieson’s 
picro fusion for evaluation by static histomorphometry, and the second section was left 
unstained for evaluation by dynamic histomorphometry. Although histological slides for 
Day 0 and Day 60 biopsies were prepared differently for ease of handling, all bony 
features were easily discernable and comparable in both sets of slides, as outlined in 
Figure 2.3 (Dempster et al., 2013).  
All biopsy sections were evaluated for quality under light microscopy as 
previously described (Steiger et al., 1999). In short, cortical and trabecular bone in each 
section were evaluated using a semi-quantitative scale whereas tissue was determined 
to be useless (0), poor (1), or good (2) quality. Three individuals (including one boarded 
veterinary pathologist, one established orthopedic researcher and one graduate 
student), evaluated each slide. Some biopsies had multiple sections to evaluate and all 
sections generated a score that was then averaged for each biopsy. 
All bone histomorphometry evaluations were performed using histomorphometry 
software (Osteomeasure© Bone Histomorphometry System, Osteometrics, Inc., 
Decatur, GA, USA)  following standard procedures and nomenclature (Dempster et al., 
2013). Static histomorphometry parameters included direct measurements of: BV, 
marrow volume (Ma.V), bone surface (Crook et al.), eroded surface (ES), mineralized 
surface (Md.S), osteoblast surface (Ob.S), osteoblast number (Ob.N), osteoclast 
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number (Oc.N), osteoclast surface (Oc.S) and remodeling surface (RS). Indirect 
measurements included: Tb.N, Tb.Th, Tb.Sp and the aforementioned direct 
measurements standardized to respective areas and volumes. Dynamic 
histomorphometry included mineralizing surface per bone surface (MS/BS), mineral 
apposition rate (MAR) and the bone formation rate per bone surface (BFR/BS).  
 
 
Figure 2.3 Labeled histological sections of bone biopsies. Representative A) decalcified 
and B) un-decalcified histological sections of biopsy 2 (Day 60), highlighting similar 
trabecular bone features. Abbreviations: B, bone; BM, bone marrow. Black arrows = 
osteoblasts; white arrows = osteocytes.  
 
Statistics 
 To evaluate slide quality, trabecular bone quality scores were averaged and the 
standard deviation was calculated. To evaluate the effect of tiludronate on bone, 
microCT and histomorphometry data were analyzed using independent analyses 
between treatment groups, as well as dependent analyses between biopsies. Data were 
tested for normality using the Shapiro-Wilk test and depending on normality, either 
parametric or non-parametric analyses were used (i.e., Student’s t-test or related 
samples Wilcoxon signed rank test, respectively). A related-sample test was used to 
	42	
evaluate changes from biopsy 1 (Day 0) to biopsy 2 (Day 60) within the control or 
treated horses. An unrelated-sample test was performed to evaluate difference between 
treated and control horses within biopsy 2. Statistical analyses were performed using 
commercially-available software (SPSS, version 22, IBM Corporation, Armonk, NY, 
USA), and p-values of <0.05 were considered significant.  
 
2.3 Results 
Surgical Technique 
 Horses received between 408 – 500 mg (mean ± SD, 474.6 ± 38.6 mg) of 
tiludronate based on weight. Only one of the ten horses in the study experienced 
incisional dehiscence, but this complication resolved with minimal medical intervention. 
All of the other 19 biopsies healed uneventfully, with no horses displaying any rear limb 
lameness or ratable discomfort at any time over the duration of this study. All biopsies 
obtained were adequate for all analyses (mean volume of 3123.72 mm3 ± 1495.37 mm3 
(SD) as measured via microCT) (Mitchell et al., 2017).  
 
MicroCT 
The biopsies were consistent in size and shape between both biopsies and treatment 
groups (Figure 2.4). No significant differences in TV were identified between treatment 
groups or biopsy as evaluated by microCT (Figure 2.5). Overall, tiludronate did not 
significantly alter bone morphology parameters after 60 days when compared to saline. 
In addition, there were no significant differences in morphology parameters between 
biopsies within treated horses or control horses (Figure 2.5). 
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Figure 2.4 Representative Day 0 bone biopsies for control (A,C) and treated (B,D) 
horses, showing the entire biopsy, excluding cortical bone (A,B), and a visually-
sectioned view (C,D), highlighting the trabecular bone architecture. The ventral face is 
the surgically-cut surface. Bar = 2 mm. 
 
Histopathology and Slide Quality 
Microscopic examination showed all sections consisted of irregularly triangular, dome-
shaped, or rectangular sections of mature bone containing variable amounts of compact 
cortical bone and attached ligaments, tendon and associated skeletal muscle, lamellar 
trabecular bone and marrow spaces. The quality of the trabecular bone within all 
biopsies was good (Figure 2.6), with adequate bony tissue for evaluation trabecular 
bone.  
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Figure 2.5 Summary data (mean ± SD) of bone structure and remodeling parameters from biopsy 1 (Day 0) and biopsy 2 
(Day 60) for microCT analyses, static histomorphometry analysis and dynamic histomorphometry analysis in control (n=5) 
and treated (n=5) horses. Abbreviations: BV/TV, bone volume fraction (bone volume/total volume); Tb.Th, trabecular 
thickness; Tb.N trabecular number; BS/BV, bone surface/bone volume; Ob.N/TA, number of osteoblasts per tissue area; 
Oc.N/TA, number of osteoclasts per tissue area; sL.S/BS, single label surface per bone surface; dL.S/BS, double label 
surface per bone surface; MAR, mineral apposition rate. aSignificant (P ≤ 0.05) difference between values with the same 
letter superscript. P-value results from related samples Wilcoxon Signed Rank Test. 
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Figure 2.6 Mean (±SD) histological bone biopsy scores from each horse enrolled in the 
study. The quality scores were categorized as follows: useless (0), poor quality (1), 
good quality (2).   
 
Sections contained variable amounts of artifact from collection, including 
presence of bone dust, mild hemorrhage, coagulative necrosis of skeletal muscle or 
bone and rare trabecular fractures. In most sections, these artifacts were present at the 
margins of the sections examined, only rarely extending into more central aspects of the 
sections, and therefore did not affect interpretations of the majority of the tissue sample.  
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Any area of compromised architecture or artifact did not extend any more than 2 mm 
away from the cut surface in any of the biopsies. 
Most horses (8/10) and most sections (12/18) showed variable sized foci of mature 
hyaline cartilage present scattered throughout the endocortical spaces. These were rare 
(one - three small islands) in some sections, but numerous in others. Foci ranged from 
irregularly round or oval, to polygonal to linear, and were frequently surrounded by 
variable amounts of mature, lamellar trabecular bone. Occasionally, within the round to 
oval foci, the hyaline cartilage surrounded an open central region containing blood 
vessels within adipose and loose fibrous connective tissues (Figure 2.7A). In some 
cartilage islands, there were variably sized regions of necrosis or areas of 
mineralization. Occasionally, the chondrocytes within the viable areas of cartilage 
formed distinct rows and demonstrated ordered chondrocyte maturation, similar to that 
seen in physeal growth plates (Figure 2.7B). These features were especially prominent 
in more linear foci of hyaline cartilage. In some sections, there were more subtle foci of 
mineralized cartilage completely surrounding by and embedded in mature, lamellar, 
trabecular bone (Figure 2.7C). There were variable amounts of mature hyaline or 
fibrocartilage blending with the adjacent ligament at the margins of most sections along 
the periosteal surface of the cortical bone, consistent with ligament attachment sites. 
Occasionally, irregularly linear tongues of cartilage extended from these regions into the 
adjacent marrow spaces (Figure 2.7D).  In addition to the apophyses, these sections 
contained individual foci of hyaline cartilage within the endocortical spaces. Some of 
these foci were closely associated with the growth plate and/or hyaline cartilage within 
areas of ligament attachments. 
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Figure 2.7 Histologic images of cartilage foci within endocortical spaces. A) Hyaline 
cartilage with central region composed of loose fibrous connective and adipose tissues 
(bounded by arrowheads) containing numerous blood vessels (red arrows). B) Cartilage 
with chondrocyte maturation (black arrows). C) Mineralized cartilage foci (bounded by 
green arrowheads) embedded within mature trabecular bone. D) Cartilage tongues 
(blue arrows) extending from a site of ligament attachment (yellow arrowheads) into 
endocortical space. 
 
 Additional samples from 3 horses of a range of ages (i.e., 9 months, 1 year, 25 
years) not included in the experiments were examined for comparison to the study 
horses. The sections from the 9-month and 1-year-old horses were histologically similar 
and contained linear, mature growth plate cartilage within the endocortical space, 
consistent with an apophyseal growth plate. These apophyses exhibited normal 
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chondrocyte maturation including distinguishable resting, proliferative, hypertrophic, and 
mineralization zones (Figure 2.8).  
In addition to the apophyses, these sections contained individual foci of hyaline 
cartilage within the endocortical spaces, similar to those present in the previously 
described study samples. Some of these foci were closely associated with the growth 
plate and/or hyaline cartilage within areas of ligament attachments. In one section of the 
1-year-old horse, there was an area within the peripheral cortical hyaline cartilage that 
demonstrated orderly chondrocyte maturation similar to that within the apophysis 
(Figure 2.8B). In contrast to the study animals, the marrow spaces in these two animals 
was often highly cellular. 
 In the 25-year-old horse, there was a single small focus of mineralized cartilage 
embedded within trabecular bone. There were no other regions of hyaline cartilage 
within the endocortical space. At the ligament attachment sites associated with the 
cortical bone, there was less cartilage present than in the previously described slides.  
 
Figure 2.8. Histologic images from juvenile horse demonstrating active bone formation. 
(A) Histologic image containing an apophyseal growth plate with distinct resting, 
proliferation, hypertrophic, and mineralization zones; (B) Histologic image 
demonstrating a region of bone formation associated with the hyaline cartilage at a 
ligament attachment site.  
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The cartilage present consisted of fibrocartilage, rather than hyaline cartilage. The 
marrow spaces contained adipose tissue and no cellular bone marrow. 
 
Histology 
 As evaluated using static histomorphometry, no significant differences were 
identified between treatment groups. When comparing biopsies within each treatment 
group, tiludronate significantly decreased trabecular thickness (p=0.02) and increased 
BS/BV ratio (p=0.048) when comparing Day 60 biopsies to Day 0 biopsies. Some 
measurements were significantly different when comparing the Day 60 biopsy to the 
Day 0 biopsy for the saline group: a decrease in RS/BS (p=0.04), decrease in BS/TV 
(p=0.04), decrease in Oc.N/TA (p=0.04) (Figure 2.5) and a decrease in Oc.S/BS 
(p=0.04).  
 As evaluated using dynamic histomorphometry, after 60 days, tiludronate did not 
significantly alter bone remodeling parameters when compared to saline. Overall, bone 
apposition rates and bone turnover was very similar between treated and control groups 
(Figure 2.5). 
 
2.4 Discussion 
 This report describes the effect of a single administration of tiludronate on bony 
cells, trabecular bone morphology and bone remodeling in ten clinically healthy, young 
horses. A previous study utilizing a bone biopsy model attempted to elucidate changes 
in bone morphology secondary to tiludronate treatment in horses, but, the samples 
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obtained were inadequate for evaluation of bone morphology and remodeling (Delguste 
et al., 2011). Thus, to our knowledge, this is the first reported study evaluating the 
cellular and structural effect on bone secondary to tiludronate administered in horses. 
There were no significant effects of tiludronate (1 mg/kg, IV) on bony cells or bone 
structure and remodeling parameters 60 days after a single administration in young 
horses. Although a few parameters were significantly different for the control group, we 
believe that these are changes that could occur during normal bone turnover in young 
horses, and these select changes do not make substantial biological sense when all 
variables are considered. It is possible, however, that these are select bony changes 
that occur during normal bone turnover in young horses, and tiludronate prevented 
similar changes from occurring. No differences were noted between treatment groups 
within the same biopsy. Although there was a significant increase in trabecular 
thickness between biopsies in horses treated with tiludronate, as determined by static 
histomorphometry, this change was not corroborated with microCT evaluations, which 
provides a more comprehensive evaluation of bone morphology within the biopsies.  
It is possible that the time frame (60 days) evaluated in this study was not long 
enough to evaluate overall changes in bone remodeling. However, this time frame was 
selected based on the only published data regarding the effect of tiludronate on horses, 
which found a positive effect of tiludronate after 60 days (Denoix et al., 2003, Coudry et 
al., 2007, Gough et al., 2010). In addition, a study evaluating bone remodeling in horses 
following treatment with phenylbutazone, which, unlike tiludronate, is not utilized as a 
treatment for diseases of bone remodeling, found significant changes in MAR using 
similar sample sizes after only 30 days (Rhode et al., 2000). Therefore, if tiludronate 
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was to have an impact on bone remodeling in young horses at the dose given, it would 
be expected that normal bone apposition rates in horses should be at least minimally 
affected by tiludronate within the timeframe of the present study. However, it is possible 
that diseased bone, characterized by abnormal bone remodeling, could be impacted by 
tiludronate administration more than the results shown in this study on normal bone. A 
study that identified significant improvements in lameness secondary to distal tarsal joint 
osteoarthritis 60 days post treatment with tiludronate also identified significant 
reductions in periarticular osteophyte formation at that time point, as evaluated by 
radiographs, indicating a potential influence on bone remodeling in horses (Gough et 
al., 2010). Therefore, these data also support the chosen time point at which to identify 
potential changes in bone microarchitecture. However, future studies including 
additional time points post treatment would be required to confirm whether tiludronate 
has a significant impact on bone morphology. As such, more recent data evaluating 
effectiveness of tiludronate administration on lameness associated with navicular 
disease as evaluated by more objective force platform analyses found significant 
improvements 120 and 200 days post treatment, but not after 60 days (Whitfield et al., 
2016).  
Due to the nature of a pilot study, there was a low sample size of 5 horses per 
group. Therefore, the effect of tiludronate on bone remodeling and structure may not 
have been apparent in the data presented here. Overall, it is possible that tiludronate 
has a small effect that was not identified in the present study. However, a difference to 
some degree was expected, despite the low numbers, given the power of tiludronate as 
a modifier of bone remodeling in numerous other species (Rhode et al., 2000). The fact 
	52	
that there was no difference between treatment groups or biopsies within the same 
horse warrants further investigation into the efficacy of tiludronate as a treatment for 
diseases of bone remodeling in the horse at the current dosage recommended. 
Tiludronate therapy is widely used in the veterinary clinical setting to treat 
disorders involving abnormal bone remodeling, including distal tarsal joint osteoarthritis 
(Gough et al., 2010), thoracic & lumbar vertebral arthritis (Coudry et al., 2007) and 
dorsal metacarpal disease (Carpenter, 2012). The efficacy of tiludronate has been 
shown in young animals in other species, including a reduction of trabecular bone 
resorption adjacent to growth plates and increased bone density in skeletally immature 
rats and baboons (Geusens et al., 1992). Tiludronate has been previously evaluated for 
pathological bone changes in horses aged 4 years and older (FOI, 2014); however, 
despite the manufacturer’s recommendation to avoid administration of tiludronate to 
horses less than four years of age, clinicians are administrating this drug to horses that 
are younger than four years of age as a treatment for dorsal metacarpal disease 
(Carpenter, 2012). It is well known that younger horses undergo more rapid bone 
remodeling than skeletally mature adults (Goyal et al., 1981), so this study aimed to 
also evaluate the effect of tiludronate administration in young horses, where negative 
impacts on normal bone remodeling could result in significant clinical outcomes in 
young equine athletes. While the current study population included horses four and five 
years of age, biopsies from all horses within the study included evidence of an open 
apophysis for the tuber coxarum (Mitchell et al., 2017), indicating some degree of 
skeletal immaturity. Additionally, the same biopsy taken from a 25-year-old mare, which 
can be reasonably assumed to be skeletally mature, showed no presence of an 
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apophysis or retained hyaline cartilage foci. Thus, it appears that there is likely complete 
closure of the apophyseal growth plate and transition of the superficial hyaline cartilage 
to mature fibrocartilage associated with skeletal maturity, which was not present in the 
evaluated horses. Additionally, although subjective and not quantitatively evaluated, one 
evaluator noticed an increase in the size and number of cartilage foci in samples in the 
younger horses. However, due to the large age gap between the horses included in the 
study and the 25-year-old evaluated, it is unclear when the apophyses in the tuber 
coxarum disappear. Horses in the current study were also not strictly age-matched; 
however, the means and standard deviations for each group were almost identical. In 
addition, dependent analyses comparing biopsies within each horse were performed, 
thereby serving as a more robust analysis of changes secondary to treatment. As 
outlined above, we did not see any influence on bone remodeling or morphology in this 
young population. However, due to the small sample sizes for each age included in the 
study and the known effect of age on bone remodeling parameters, there cannot be 
definitive conclusions based on age. In addition to a larger number of horses, a smaller 
range of ages in horses may result in a significant effect on bone morphology 
parameters.  
 The iliac biopsy location utilized in the study was chosen for multiple reasons, 
despite the dissimilarities in architecture and biomechanics to weight bearing bones 
found in the equine distal limb, such as the metacarpal bones. Most importantly, the 
tuber coxarum is an easily accessible location that allowed for a non-terminal biopsy 
model in the equine, and provides the opportunity for multiple biopsies from the same 
horse over set time points (Mitchell et al., 2017). Various sites for bone biopsy have 
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been described in standing sedated, anesthetized and euthanized horses (Delguste et 
al., 2011). These locations include the sternebrae, ribs, tuber coxae, the third 
metacarpal bone, and the fourth tarsal bone (Misheff et al., 1992, Steiger et al., 1999, 
Désévaux et al., 2000, Delguste et al., 2011). Biopsies obtained in these studies have 
ideally been as small as possible due to the relative size of the bone being sampled 
(ribs) or due to the load-bearing nature of the bone (metacarpus) (Firth, 2004). Biopsies 
obtained from weight bearing bones, such as the metacarpals and tarsal bones, 
deemed of adequate size for histologic examination would likely result in lameness or 
euthanasia of the horse. In addition, these samples would provide little, if any, 
trabecular bone for examination, as these bones are composed of predominantly 
cortical bone. Larger biopsies from non-weight-bearing bones provides more data for 
consistent histological and architectural examination, as shown in this study.  
 Despite the differences in biomechanics, bone remodeling of the tuber coxarum 
has been shown to accurately predict the effect of alendronate, another form of 
bisphosphonate, on non-homogenous skeletal locations in the body (i.e., vertebral 
column) (Mashiba et al., 2005). This location was chosen for the biopsy site for the 
additional reason that it has been shown that bisphosphonates accumulate at the 
highest density in tuber coxae when compared to other bones in the equine, including 
bones that experience more biomechanical stress, such as the 3rd metacarpal, rib and 
cuboid bone (Delguste et al., 2011). An added benefit of this biopsy technique was the 
relatively large biopsy size, which allowed multiple study endpoints to be utilized. The 
second biopsy was prepared for undecalcified histology in order to preserve the 
fluorescent label, which required different preparation than the initial biopsy received. 
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Although preparation methods varied, methods of analyses and outcome measures 
were identical for both preparation methods of static histomorphometry sections 
(Dempster et al., 2013).  
It is important to recognize that this technique for biopsy has potential to include 
the apophyseal growth plate or remnants thereof, particularly in younger horses. The 
specific apophyses in the bones of the pelvis in the horse are not well described and the 
presence of an apophysis in the tuber coxarum has not been substantiated in the 
literature of domestic quadrupeds. The identification of an apophysis in the tuber 
coxarum is an important finding and the presence of cartilaginous foci should be noted 
for future studies using this biopsy method as it may bias assessment of trabecular 
bone that rely on counts of trabecular number and spacing. However, the presence of 
these foci do provide a potentially unique opportunity for investigators examining 
changes in bone growth and physeal activity in horses.  
 In conclusion, this study describes a simple tuber coxarum biopsy procedure for 
horses that is well tolerated and produces samples large enough to be sectioned 
multiple times, permitting several methods of analyses to evaluate bone morphology 
and remodeling in a non-terminal model. It appears that tiludronate does not have a 
substantial impact on normal bone remodeling kinetics and morphology in young horses 
60 days post treatment. Overall, tiludronate does not appear to impact bone remodeling 
parameters in young horses, and has minimal to no effect on bone morphology 
parameters after 60 days.  
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CHAPTER 3. 
INFLUENCE OF CLODRONATE ON BONE CELLS, MORPHOLOGY, REMODELING 
AND HEALING IN YOUNG HORSES 
 
3.1 Introduction 
 Recently, the FDA approved the use of Clodronate disodium (Osphos, Dechra, 
Ltd., Staffordshire, UK) as a treatment for navicular disease in the horse (FOI, 2014). 
Clodronate is a non-nitrogen containing bisphosphonate that reduces osteoclastic bone 
resorption by causing osteoclast apoptosis (Lehenkari et al., 2002). Clodronate is 
similar to tiludronate, which has been used extensively to treat conditions associated 
with bone remodeling, such as navicular disease (Denoix et al., 2003, Whitfield et al., 
2016) and tarsal osteoarthritis (Gough et al., 2010). However, unlike tiludronate, 
clodronate has been shown to have an analgesic effect by acting on glutamate and/or 
ATP-related pain transmission pathways (Shima et al., 2016). The Freedom of 
Information (FOI) Summary (FOI, 2014) reports on the clinical outcome in a group of 
horses diagnosed with navicular disease, treated with either clodronate or saline. At 56 
days post-treatment, 68 of 86 clodronate-treated horses had improved by one score of 
the American Association of Equine Practitioner (AAEP) lameness scale, compared to 1 
of 28 saline-treated horses (FOI, 2014). However, it is unclear whether the reduction in 
lameness in the aforementioned study (FOI, 2014) is due to clodronate treatment’s 
effect on pathological bone remodeling, or its analgesic potential.  
 The FOI summary describes the effects of clodronate on bone mineral content, 
cortical bone strength and bone marrow evaluation evaluated by radiographic 
photometry, mechanical testing and histopathology, respectively, in normal horses. 
They reported no difference in these parameters between treated and saline controls at 
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6 months (FOI, 2014). However, the methods regarding how bone density data were 
obtained were not stated, and given the poor sensitivity of radiographs to determine 
bone density (Moyad, 2003), it is uncertain whether there was or was not an effect on 
bone in this cohort. Despite its known effect on bone remodeling rates in other species, 
the effect of clodronate on bone healing, especially in the horse, is unclear. In animal 
models, clodronate has been found to not alter endochondral bone formation within the 
callus or epiphyseal plate of rats (Nyman et al., 1996, Madsen et al., 1998), but reports 
show conflicting alterations to callus and bone properties, including no changes in bone 
mineral density (Koivukangas et al., 2003), 30% increase in bone mineral density 
(Madsen et al., 1998), increased calcium content within the callus (Nyman et al., 1993) 
and decreased healing callus strength (Tarvainen et al., 1994). Recently, it has been 
shown that osteoclasts are a necessary component of efficient endochondral 
ossification during fracture repair in mice (Lin and O'Connor, 2016); therefore, it is 
possible that clodronate may impair normal bone healing in horses, which calls for 
careful consideration when used in a clinical setting.  
 Therefore, the purpose of this study is to evaluate the effect of clodronate on 
bone morphology, bony cells, bone remodeling, and bone healing in young horses. 
These evaluations were performed by obtaining bone biopsies of the tuber coxarum 
using an established technique (Mitchell et al., 2017), and evaluated through 
histomorphometry and microCT. To evaluate bone healing, subsequent biopsies were 
taken from the initial biopsy site, which served as a novel bone defect model in the 
horse. We hypothesized that clodronate would reduce osteoclast number and function, 
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resulting in increased bone volume and increased bone apposition, as well as increased 
bone formation after injury.  
 
3.2 Materials and Methods 
Study Design 
The experimental protocol used for this study was approved by the Louisiana 
State University IACUC (Protocol #15-081). Nine clinically healthy Thoroughbred 
horses, aged two – four years of age, were used in the study. Horses were obtained 
through donation, and did not have a known medical history prior to inclusion within the 
herd at the institution’s facility. However, all horses underwent at least a two-week 
washout period prior to enrollment in the current study. Horses were randomly assigned 
using a coin flip to either a treatment (n=5) or control (n=5) group. Sample sizes were 
determined based on donation availability, and all eligible horses were considered. 
Additionally, if eligible horses became available during the course of data collection, 
they were evaluated and included in order to maximize sample size. A coin flip was 
used to randomly assigned horses to a treatment group (i.e., clodronate or saline), and 
only the surgeon knew group assignments until subsequent statistical analyses on data 
collected were ready to be performed. 
Bone biopsies were taken from each horse; a baseline biopsy at Day 0, and a 
contralateral (Day 60) and ipsilateral re-biopsy of the initial site (Day 60R) 60 days after 
treatment (Figure 3.1). The initial biopsy side was randomly selected via coin flip. 
Subsequent to the initial biopsy collection (Day 0), each horse was administered 
clodronate (1.8 mg/kg, via IM injection, with the total volume divided into three injection 
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locations), or equal volume of 0.9% saline. This dose and route of administration is 
standard in the field (FOI, 2014). Prior to the second biopsy collections, the 
fluorochrome label oxytetracycline (Vetrimycin 100, VetOne, Boise, ID, USA) was 
administered at Day 47 and Day 57 to detect bone remodeling parameters. At Day 60, 
two additional biopsies were collected using the same procedure. Analyses of all 
biopsies included microCT and histomorphometry evaluations for changes in bone 
morphology, remodeling rates, and bone healing.    
 
 
Figure 3.1 Clodronate study design schematic of time line, outlining biopsy collection 
and treatment administration. Abbreviations: Contra., Contralateral; Ipsi., Ipsilateral. 
 
Study Horses 
Thoroughbred horses were included for use in the study if they were clinically 
healthy and free from apparent musculoskeletal disease, determined through a physical 
examination, and were aged 3 to 4 years old (mean weight (± SD): 431.9 ± 52.4). 
Horses were housed individually in stalls following surgeries, and were returned to their 
respective group pastures after 24-48 hours post-operation, with free choice hay and 
water and grain twice daily.  
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Surgical Procedure & Treatment 
The surgical methods utilized in this study have been previously published in detail 
(Mitchell et al., 2017). Briefly, surgeries were performed while horses were restrained in 
stocked and sedated with intravenous (IV) xylazine (Xylamed, Bimeda, Cambridge, ON, 
Canada) (0.35 to 0.5 mg/kg). A 10 cm by 10 cm square was centered over the palpable 
area of the tuber coxarum and was aseptically prepared. Local anesthetic (i.e., 
Lidocaine 2%, VetOne, Boise, ID, USA) was injected subcutaneously superficially down 
to the tuber coxarum periosteum, and horses were further sedated with detomidine 
hydrochloride (Dormosedan, Zoetis, Kalamazoo, MI, USA) (3 to 5 mg IV) and 
butorphanol tartrate (Torbugesic, Fort Dodge, New York, NY, USA) (3 to 5 mg IV)). A 
vertical incision was made over the tuber coxarum and was dissected to expose the 
cranial, caudal, deep and proximal margins. An oscillating saw was used to cut the 
proximal portion of the tuber coxarum, with constant saline lavage to limit thermal 
damage. After biopsy removal, the site was lavaged, and sutured closed (Mitchell et al., 
2017). Flunixin meglumine (Prevail, Bimeda, Cambridge, ON, Canada) (1.1 mg/kg IV) 
was administered as an additional analgesic and the treatment (either clodronate or 
saline) was administered IM. 
Following the initial biopsy, horses were stalled for 24-48 hours and monitored for 
signs of pain (Doherty and Valverde, 2006). Horses were returned to their group 
pastures and monitored daily for complications or lameness until sutures were removed 
14 days later. At Day 47 and 57 post biopsy, the bone fluorescent label oxytetracycline 
(25 mg/kg) was administered slowly IV. Sixty days after the initial biopsy, two additional 
biopsies were collected; the contralateral side (Day 60 biopsy) and a re-biopsy of the 
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initial biopsy side (Day 60R biopsy) to evaluate bone healing. Biopsies were obtained 
using the same surgical methods as described above. However, careful consideration 
was made when placing the oscillating saw for the re-biopsy to ensure an adequately-
sized biopsy of the tuber coxarum was obtained without cutting into the pelvis. Surgical 
aftercare was identical.  
 
MicroCT 
Following biopsy collection, soft tissue was removed from tuber coxae samples, 
and biopsies were fixed in 10% non-buffered formalin for 7 days. After fixation, biopsies 
were stored in 70% ethanol at 20˚C. For microCT (Scanco model 40, Scanco Medical 
AG, Basserdorf, Switzerland) evaluation, biopsies were placed in scanning holders with 
70% ethanol, and scanned at 55kV, 0.3-second integration time, with a 30 µm voxel 
size in plane and a 30 µm slice thickness. Trabecular bone was selected as the region 
of interest, and the proper segmentation threshold was determined and used throughout 
for all samples. Trabecular bone was evaluated for bone volume (BV), total volume 
(TV), BV/TV, tissue mineral density, trabecular number (Tb.N), trabecular thickness 
(Tb.Th), trabecular spacing (Tb.Sp), connectivity density (Con.D), and structural model 
index (SMI) based on established procedures and nomenclature (Bouxsein et al., 2010). 
 
Histology 
After microCT evaluation, biopsies were prepared for histology as previously 
published (Mitchell et al., 2017). Day 0 and Day 60R biopsies were prepared for 
decalcified histology, and Day 60 biopsies were prepared for undecalcified histology so 
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visualization of fluorochrome labels was possible. Overall, histological preparation of 
biopsies differed slightly due to preparation technique required and the necessary size 
of the histologic slides. However, careful considerations were made to ensure sections 
of each biopsy were taken from the same location and plane of section. Day 0 and Day 
60R biopsies were decalcified with 10% ethylenediaminetetraacetic acid (EDTA) and 
prepared for routine paraffin embedding. Day 0 and Day 60R biopsies were split in half 
and embedded separately, resulting in 6 – 8, 4 µm thick sections per biopsy, and were 
stained with hematoxylin and eosin (H&E). Day 60 biopsies were prepared intact for 
routine undecalcified histology, producing two, 45-60 µm thick sections. One section 
was stained with Stevenel’s Blue and Van Gieson’s picro fusion to evaluate bony cells 
and bone morphology via static histomorphometry, and the other section was left 
unstained for evaluation of bone remodeling via dynamic histomorphometry.  
Histomorphometry evaluations were performed using standard software 
(Osteomeasure© Bone Histomorphometry System, Osteometrics, Inc., Decatur, GA, 
USA)  following standard procedures and nomenclature (Dempster et al., 2013). Static 
histomorphometry parameters included direct measurements of: BV, marrow volume 
(Ma.V), bone surface (Crook et al.), eroded surface (ES), osteoblast surface (Ob.S), 
osteoblast number (Ob.N), osteoclast number (Oc.N), and osteoclast surface (Oc.S). 
Indirect static histomorphometry measurements included: Tb.N, Tb.Th, Tb.Sp, and the 
direct measurements list above standardized to respective areas and volumes. Dynamic 
histomorphometry parameters included mineralizing surface per BS (MS/BS), mineral 
apposition rate (MAR) and the bone formation rate per BS (BFR/BS). 
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Statistics 
To evaluate the effect of clodronate, microCT and histomorphometry data were 
analyzed using independent analyses between treatment groups, as well as dependent 
analyses between biopsies (Figure 3.2). Prior to statistical comparisons, data were 
tested for normality using the Shapiro-Wilk test. Depending on normality, either 
parametric or non-parametric analyses were used for each parameter (i.e., paired 
Student’s t-test, related samples Wilcoxon signed rank test, independent Student’s t-test 
or independent samples Mann-Whitney U test). A related-sample test was used to 
evaluate changes from Day 0 biopsy to Day 60 biopsy, or Day 0 biopsy to Day 60R, 
within the control or treated horses. An unrelated-sample test was performed to 
evaluate difference between treated and control horses within Day 60 biopsy or Day 
60R biopsy. Statistical analyses were performed using commercially-available software 
(SPSS, version 24, IBM Corporation, Armonk, New York, USA), and p-values of <0.05 
were considered significant. If a parameter was significant but not normalized to 
respective biopsy size measurements, it was not reported (e.g., BV versus BV/TV). Due 
to the aforementioned issues with obtaining microCT data from two Day 0 biopsies, all 
data from those horses were excluded from dependent analyses. 
 
3.3 Results 
Surgical Technique 
 One horse (control group) was lost during the study and was euthanized due to 
reasons unrelated to the study, and was therefore not included in subsequent analyses.   
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Figure 3.2 Schematic of statistical comparisons for microCT and histomorphometry 
data. 
 
Horses received between 660 – 800 mg (mean ± SD, 783.0 ± 81.8 mg) of clodronate 
based on weight. All surgeries were successful in obtaining adequately-sized bone 
biopsies during each attempt, with no horses showing post-surgical lameness or 
complications. Day 0, Day 60 and Day 60R biopsies had a mean (± SD) TV of 1731 ± 
78, 1467 ± 453 and 1080 ± 646 mm3, respectively. 
 
Bone Morphology 
 Due to technical difficulties, microCT analyses were only performed on three of 
the five Day 0 biopsies from the treated group. When comparing data from treated 
horses to control horses within the Day 60 biopsy, there was no significant effect of 
clodronate treatment on any of the 19 total bone morphology parameters as evaluated 
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by microCT (Figure 3.3). Similarly, there were no significant changes in bone 
morphology parameters between Day 0 and Day 60 biopsies within treated horses, or 
within control horses, as evaluated by MicroCT.  
  When comparing Day 0 biopsy to Day 60 biopsy within the control horses, 
several histomorphological parameters were significantly different: Day 0 biopsy was 
significantly greater than Day 60 biopsy in BV/TV (p=0.02) (Figure 3.3), and Oc.S/BS 
(p=0.04), and Day 60 biopsy was greater than Day 0 biopsy in Tb.Sp (p=0.01) and 
Ma.V/TV (p=0.02). When making the same comparison within treated horses, Day 0 
biopsy was greater than Day 60 biopsy in Void Surface/BS (p=0.049), and Ob.N/TA 
(p=0.03) (Table 1), and Day 60 biopsy was greater than Day 0 biopsy in 
Ob.N/Ob.Perimeter (p=0.02). Overall, changes from Day 0 to Day 60 within control 
horses affected three out of 20 bone morphology parameters, and one out of 10 bone 
resorption parameters. Changes from Day 0 to Day 60 within treated horses showed 
differences in one out of 20 bone morphology parameters, and two out of 20 bone 
formation parameters.  
 
Bone Remodeling 
 After 60 days, clodronate did not significantly alter any of the 14 bone remodeling 
parameters evaluated via dynamic histomorphometry (Figure 3.3).  
 
Bone Healing 
 When comparing treated horses to control horses within the Day 60R biopsy, 
there was no significant effect of clodronate on any of the 19 bone morphology 
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parameters, as evaluated by microCT. Comparing Day 0 biopsy to Day 60R biopsy 
within control horses and then again within treated horses, there were no significant 
differences in any of the 19 bone morphology parameters evaluated via microCT. 
 When comparing Day 0 to Day 60R within control horses, the Day 60R biopsy 
had significantly higher ES/BS (p=0.049). Comparing Day 0 biopsy to Day 60R biopsy 
within treated horses, the same effect in ES/BS (p=0.03) was observed. Comparing 
treated horses to control horses within the Day 60R biopsy, treated horses had 
significantly higher BS/TV (p=0.02) and Tb.N (p=0.02), and significantly less Ob.S/BS 
(p=0.04). Overall, two out of 20 bone morphology parameters and one out of 20 bone 
formation parameters were significantly affected. 
 
3.4 Discussion 
 This study details the effect of a single dose of clodronate on bone cells, 
morphology, remodeling, and healing in 5 healthy, young Thoroughbred horses. This is 
the first study that has evaluated bony changes due to clodronate in the horse, despite 
its prolific use in veterinary clinics. Additionally, clodronate’s effect in horses under 4 
years of age has not been determined. Overall, the data presented here demonstrates 
that overall there were no effects of clodronate after 60 days on bone morphology or 
remodeling when compared to the control group and when compared to baseline 
biopsies from the same horse, using the prescribed dose and route of administration.  
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Figure 3.3 Summary data (mean ± SD) of bone structure and remodeling parameters from Day 0, Day 60 and Day 60R 
biopsies for microCT, static histomorphometry and dynamic histomorphometry analyses in control (n=4) and treated (n=5) 
horses. Abbreviations: BV/TV, bone volume fraction (bone volume/total volume); Tb.Th, trabecular thickness; Tb.N 
trabecular number; Con.D, connectivity density; Ob.N/TA, number of osteoblasts per tissue area; Oc.N/TA, number of 
osteoclasts per tissue area; sL.S/BS, single label surface per bone surface; dL.S/BS, double label surface per bone 
surface; MAR, mineral apposition rate; BFR/BV, rate of bone formation (bone formation rate per unit of bone volume). 
a,bSignificant (P ≤ 0.05) difference between values with the same letter superscript. P-value results from paired Student’s 
t-test.  * Sample size for treated Day 0 biopsies contains 3 horses for microCT analysis.  
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 One limitation to the current study is a lack of evaluation in a model of 
pathological bone remodeling, and a lack of clinical evaluations on lameness. However, 
a barrier to the field is that there is currently no data regarding whether clodronate does 
or does not affect bone remodeling in the horse at the doses administered. It is well 
known that bisphosphonates are powerful modifiers of the bone remodeling process, 
including in normal bone (Mashiba et al., 2005). Therefore, it is hypothesized that if 
there were a systemic effect of clodronate administration in the horse at the routine 
clinical dose administered, it would have been detected in the current study. As outlined 
above, treatment success in the previous study (FOI, 2014) may have been based on 
clodronate’s pain-minimizing properties, and not due to changes in bone remodeling. 
This would explain the treatment success demonstrated in that clinical trial (FOI, 2014), 
but support the lack of bony changes shown in this study. However, a novel aspect of 
the current study is the evaluation of the effect of clodronate on bone healing secondary 
to a bone defect (i.e., the biopsy). Bone healing during clodronate use has been 
evaluated in rats (Madsen et al., 1998, Koivukangas et al., 2003), with no reports of 
adverse effects on bone remodeling (Koivukangas et al., 2003), but conflicting results 
on bone callus formation during fracture repair (Nyman et al., 1993, Nyman et al., 1996, 
Madsen et al., 1998). In this study, although not specifically evaluating fracture repair, 
we too found minimal effects on bone healing after injury. 
The biopsy location, the tuber coxarum, used in the current study may not be 
representative of normal bone remodeling throughout the equine skeleton. However, 
previous work has shown that tiludronate, a bisphosphonate similar in structure and 
pharmacokinetics to clodronate (Lin, 1996), has been shown to accumulate in the bone 
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at highest concentrations within tuber coxae (Delguste et al., 2011). Thusly, while no 
such data exists for clodronate, given the similarities between tiludronate and 
clodronate, the tuber coxae are assumed to accumulate high concentrations. Similarly, 
the tuber coxae do not experience the same specific biomechanics experienced in the 
equine distal limb, specifically the navicular bone. It is possible that exercise may 
influence the effect of bisphosphonates on bone remodeling. Using the tuber coxae is a 
potential limitation in regards to conclusions about weight-bearing bones, given that 
clodronate is indicated for treatment of abnormal bone remodeling that primarily occurs 
in the distal limb in horses. However, bisphosphonates have been repeatedly shown to 
have systemic effects on bone (Drake and Cremers, 2010), especially trabecular bone 
(Pataki et al., 1997), so it can be reasonably argued that any changes that would occur 
secondary to treatment with clodronate would be identified in the selected biopsy 
location. Similarly, the pelvis has been identified as a location that can accurately 
represent changes found in weight bearing regions of the skeleton, such as the 
vertebrae (Mashiba et al., 2005).  
 While some significant differences in bone morphology were identified 
histologically, these changes were not confirmed via microCT, which represents a 
comprehensive evaluation of bone structure in three dimensions, as compared to two-
dimensional histological assessments. While histomorphometry is excellent tool for cell 
and remodeling analyses of a slice of the total biopsy, microCT accounts for the entire 
biopsy volume. Therefore, despite small differences reported, the authors conclude that 
overall effects of clodronate on bone morphology and remodeling were insignificant in 
young horses after 60 days. Overall, there were small differences noted between 
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clodronate and saline comparisons. However, these differences were minor, and do not 
make biological sense as a stand-alone parameter in the broad overview of bone 
formation and resorption. It is possible that the changes seen in the control group are 
normal bony changes for this time frame, and clodronate preventing these changes 
from occurring in the treated group. However, as the changes reported are not 
consistent with overall changes expected. The low sample size may have limited the 
overall power of our analyses, but given the known efficacy of clodronate in other 
species on altering bone resorption (Minaire et al., 1986), even a small difference, if 
present, was expected to be observed. The 60 day duration of this study is short; 
however this duration has been used in other studies examining bone remodeling 
(Rohde et al., 2000) and is associated with clinical improvement of lameness in the 
majority of horses treated with either clodronate or tiludronate (Denoix et al., 2003, 
Gough et al., 2010, FOI, 2014). Clinical improvement in lameness may not be related to 
changes in bone morphology or remodeling, but without investigating the effects in 
normal horses, pathologic changes or responses following therapy will be harder to 
identify. Additionally, our study utilized both internal controls and a separate control 
group, and found no additional differences in any parameter using these comparisons. 
However, future evaluations should utilize a larger sample size to increase power to 
determine if clodronate has minimal effect on bone remodeling.  
 In conclusion, we found that clodronate has no effect on bone morphology, as 
evaluated via microCT, and no effect on bone remodeling after 60 days in young 
horses. There were minimal effects found via static histomorphology; however, these 
results are insignificant in the absence of microCT data and other normalized 
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parameters. Additionally, we determined that clodronate does not negatively affect bone 
healing in the presence of a bone injury, in this skeletal location, after 60 days.  
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CHAPTER 4. 
ANATOMICAL VARIATION OF THE TARSUS IN COMMON INBRED  
MOUSE STRAINS2 
4.1 Introduction 
 Rodent models are widely used in orthopedic and biomechanical research, which 
rely upon accurate knowledge of the anatomy of the hind limb (Gillis and Biewener, 
2001, Settle et al., 2003, Glasson et al., 2007, Rose et al., 2013, Banzrai et al., 2016). 
Their small size, fully sequenced genome (Corsortium et al., 2002, Adams et al., 2015) 
and short lifespan make them a common candidate for translational studies related to 
human disease. Therefore, detailed and accurate anatomical descriptions are extremely 
important for any translational research that involves the musculoskeletal system of 
rodents. Prior to the advent of novel technologies that allow advanced imaging of 
various tissues and organ systems, scientists relied on artistic interpretations of 
anatomy (Cook, 1965, Rugh, 1968, Popesko et al., 1992) for references. These 
drawings are still used today as anatomical references for research and education. 
These references describe the tarsal anatomy of mice (Mus muscus) as having eight 
bones, including tarsal bones I (os tarsale I), II (os tarsale II), III (os tarsale III) and IV 
(os tarsale IV), medial tibial (tibiale mediale), central (os tarsi centrale), calcaneus and 
talus (Cook, 1965, Rugh, 1968). The anatomy of the murine tarsus, as described by 
Cook (Cook, 1965) and Rugh (Rugh, 1968), is identical to the anatomy found in the rat 
(Popesko et al., 1992). 
																																																						
2 This chapter previously appeared as Richbourg, H. A. et al. Anatomical Variation of 
the Tarsus in Common Inbred Mouse Strains. Anat Rec (2016) DOI: 10.1002/ar.23493. 
Reprinted by permission of John Wiley and Sons via RightsLink. 
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 While useful, these conventional references do not depict three-dimensional (3D) 
relationships between anatomical structures. Published anatomical descriptions have 
expanded to include high resolution, 3D images and models of anatomy derived from 
computed tomography (Yakatan et al., 1982) scans from several species. The skeletal 
anatomy of a C57Bl/6 (Black6) laboratory mouse has been characterized in extensive 
detail by utilizing microCT (Bab et al., 2007), and conflicting data describing murine 
tarsal anatomy has been observed between the established anatomical illustrations 
(Cook, 1965, Rugh, 1968) and the more recent text (Bab et al., 2007) that uses microCT 
to describe murine skeletal anatomy. When examining the tarsus in high-resolution 
microCT scans of a 10-week-old male Black6 laboratory mouse (Bab et al., 2007), the 
central tarsal bone and tarsal bone III are fused; however, this fused bone is labeled as 
the navicular bone (i.e. central tarsal bone) with no discussion on the absence of the 
tarsal bone III. Additionally, Duce et al. (Duce et al., 2010) reported difficulty in 
determining the interface between the central and tarsal bone III in Black6 mice during 
digital segmentation of micro-magnetic resonance imaging (MRI) data.  
 Normal variation in tarsal bone anatomy has been documented in several other 
species, both domestic and exotic (Shubin et al., 1995, Dyce et al., 2010). Although 
normal variation in ossification patterns within rodents has been documented (Wilson et 
al., 2010), normal variations in tarsal anatomy within mice remain undocumented. This 
lack of knowledge impacts studies that have identified abnormalities of the tarsus in 
mice afflicted with mutations affecting the expression of growth and differentiation 
factors (GDF) 5 and 6 (Grüneberg and Lee, 1973, Storm et al., 1994, Settle et al., 2003, 
Tassabehji et al., 2008). One of these mutations is characterized as brachypodism, a 
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disease that is caused by a recessive gene mutation that affects the appendicular 
skeleton, resulting in shortened long bones and fusion of bones within the tarsus and 
carpus (Grüneberg and Lee, 1973, Storm et al., 1994, Seemann et al., 2005). In these 
studies, the fusion of tarsal bone III and the central tarsal bone is represented as an 
abnormal consequence of gene mutations in commonly used inbred laboratory mouse 
strains. Due to conflicting information between these studies and anatomical references, 
documenting the detailed anatomy of the tarsal anatomy in mice is important for future 
work involving the skeletal structures in this region. Therefore, the purpose of the 
current study is to characterize the normal anatomy of the tarsus and to clarify the 
presence and number of bones within this region in normal laboratory mice, evaluating 
both young and mature individuals of multiple lineages. To determine the phylogenetic 
extent of the potentially derived tarsal anatomy observed in laboratory mice, they are 
compared with other closely related murines by evaluating the rat (Rattus norvegicus); 
and a member of Cricetidae as the outgroup, the more distantly related white-footed 
mouse (Peromyscus leucopus) (Blanga-Kanfi et al., 2009). 
 
4.2 Materials and Methods 
Study Design 
 Left hind limbs from 17 laboratory mice, 2 white-footed mice and 5 rats were 
collected. To accurately determine variation in hind limb bony anatomy, tarsi from these 
specimens were analyzed via high-resolution microCT. Three-dimensional 
reconstructions of the tarsal bone anatomy were then made for comparisons as outlined 
below. In addition, decalcified histology of the tarsus from the hind limb of one Black6 
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laboratory mouse and one BalbC laboratory mouse was analyzed to confirm tarsal bone 
fusion.  
 
Specimens 
 All specimens in this study were collected post-mortem as discarded tissues 
under approved IACUC protocols, and were not included in concurrent studies involving 
musculoskeletal disease before euthanasia. Details regarding the specimens utilized in 
the study are outlined in Figure 4.1. In short, two laboratory strains of mice (M. muscus; 
Black6, n=15; and BalbC, n=2), white-footed mice (P. leucopus, n=2) and laboratory 
rats (R. norvegicus, Sprague Dawley, n=5) were evaluated. Within the Black6 inbred 
laboratory mice, hind limbs from mice of various ages were included: 24 weeks (n=7), 
16 weeks (n=3), 11 weeks (n=3), 8 weeks (n=1) and 3.5 weeks (n=1). The left hind limb 
from each specimen was disarticulated at the coxofemoral joint and fixed in 10% 
neutral-buffered formalin prior to analysis.  
 
Micro-computed tomography and 3D reconstruction 
 Samples were scanned (Scanco Model 40, Scanco Medical AG, Basserdorf, 
Switzerland) in 70% ethanol at 55 kV, 145 μA with various isotropic voxel resolutions 
(outlined in Table 4.1) due to limb size. The region of interest (Bouxsein et al., 2010) for 
microCT scanning included the region between the distal tibia to the proximal 
metatarsal bones. Each scan was exported as a set of DICOM files and imported to the  
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Figure 4.1 Characteristics for study samples utilized, including common name, species 
name, specific strain (if applicable), age (if known), sex, the number of samples per 
category and the microCT scanning resolution. Exact ages are not known for animals 
obtained from the field, so maturation was deduced based on closure of physes within 
the hind limb. For age reference, sexual maturity of the mouse and rat is estimated to 
be as early as 4 to 5 weeks. 
 
imaging software Amira version 6.0.1 (FEI Software, Hillsboro, OR, USA). Anatomical 
features were segmented by hand, using a Wacom Intuos Pro large tablet (Wacom 
Technology Corp., Vancouver, WA, USA). Standard veterinary anatomical 
nomenclature was utilized throughout the study (Nomenclature, 2012). 
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Histology 
 Following microCT scanning, a representative hind limb from one Black6 and 
BalbC laboratory mouse were prepared for routine decalcified histology. The hind limbs 
were decalcified in 10% ethylenediaminetetraacetic acid (EDTA) for two weeks, 
processed, embedded intact into paraffin and serially sectioned in the sagittal plane. 
Four to five representative sections were selected through the central tarsal region, 
ensuring inclusion of the central tarsal bone and tarsal bone III, and stained with 
hematoxylin & eosin (H&E). Sections were evaluated for presence of joint space, 
hyaline cartilage and/or subchondral bone.  
 
4.3 Results 
MicroCT and Digital Models  
The laboratory mouse tarsus has seven individual tarsal bones: the calcaneus, 
talus, fused central and tarsal bone III, medial tibial bone and tarsal bones I, II, and IV 
(Figure 4.2). The tibia and fibula articulate distally with the talus, and the tarsocrural joint 
incorporates the distal tibia and fibula, talus and calcaneus. The proximal row of tarsal 
bones includes the medial tibial bone, talus and calcaneus. The talus articulates with 
the calcaneus caudally, medial tibial bone medially and the fused central and tarsal 
bone III distally. The middle row of tarsal bones is composed of the proximal portion of 
tarsal bone I, proximal portion of the fused central and tarsal bone III and tarsal bone IV 
(medial to lateral), and the distal row consists of the distal portion of tarsal bone I, tarsal 
bone II, distal portion of the fused central and tarsal bone III and the distal portion of 
tarsal bone IV (medial to lateral). The metatarsals are distal to the tarsal bones, 
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consisting of (medial to lateral) metatarsals I, II, III, IV, and V. Each metatarsal bone 
articulates with the corresponding tarsal bone (i.e., metatarsal I articulates with tarsal 
bone I), with the exception of metatarsal V, which articulates with the distal portion of 
tarsal IV. Metatarsal V protrudes the furthest proximally of the metatarsals.  
 In contrast, the rat and white-footed mouse have a separate central tarsal bone 
and tarsal bone III (Figure 4.2), consisting of 8 separate tarsal bones (full pes shown in 
Figure 4.3). Two-dimensional slices from microCT scans confirm fusion of the central 
and tarsal bone III in both strains of laboratory mice, and separation in the rat (Figure 
4.4). In this particular white-footed mouse specimen, metaphyseal physes were not 
ossified in the proximal and distal tibia, proximal and distal fibula, proximal metatarsal I 
and metatarsal V; in addition, the apophysis that gives rise to the tuber calcanei was not 
ossified, indicating that this specimen was skeletally immature. Similar to the white-
footed mouse, metaphyseal physes were not ossified in the tibia, fibula and metatarsal I 
in the 3-week- old Black6, and the fibula in the 8-week-old Black6. Similarly, the 
apophysis that gives rise to the tuber calcanei was not ossified in the 3- and 8-week-old 
specimens. Comparative tarsal anatomy of the laboratory mouse, rat and white-footed 
mouse are shown in Figure 4.5.  
 
Histology 
Sagittal sections of the tarsus in both the adult Black6 and BalbC mice show a 
single, fused central and tarsal bone III (Figure 4.6). In both samples, a horizontal band 
of healthy hyaline cartilage was present near the approximated fusion site, but is 
surrounded by healthy and intact trabecular bone.   
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Figure 4.2 Representative 3D reconstructions of the left tarsus (cranial view) of A) adult 
Black6 mouse, B) adult BalbC mouse, C) 8 week old Black6 mouse, D) 3.5 week old 
Black6 mouse, E) rat, and F) white-footed mouse. Abbreviations: Cal, calcaneus; Cen, 
central tarsal bone; Cen & T3, fused central and tarsal bone III; Fib, fibula; Med T, 
medial tibial bone; Met, metatarsals; Ses, sesamoid; Tal, talus; Tib, tibia; T1, tarsal 
bone I; T2, tarsal bone II; T3, tarsal bone III; T4, tarsal bone IV. Scale bar = 0.5 mm. 
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Figure 4.3 Three-dimensional reconstructions of the left pes of the white-footed mouse 
(P. leucopus) in medial, cranial and lateral view from left to right. Abbreviations: Cal, 
calcaneus; Cen, central tarsal bone; Fib, fibula; Med T, medial tibial bone; Met1, 
metatarsal I; Met5, metatarsal IV; Ses, sesamoid; Tal, talus; Tib, tibia; T1, tarsal bone I; 
T2, tarsal bone II; T3, tarsal bone III; T4, tarsal bone IV. Scale bar = 2.5 mm.  
 
4.4 Discussion 
In this study, we determined that the fusion of the central and tarsal bone III is present 
in both strains of laboratory mice examined. Considering that the fusion was present in 
all individuals of varying ages (n=17), we conclude this to be a ubiquitous tarsal 
characteristic in laboratory mice. In addition to microCT evaluations, histology further 
confirmed this fusion. Our findings contradict the majority of previously published data 
(Cook, 1965, Rugh, 1968, Popesko et al., 1992) but support the recent images  
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Figure 4.4 Representative sagittal (A, C, E) and transverse (B, D, F) slices from 
microCT scans showing the central (purple) and tarsal bone III (blue) in the adult Black6 
mouse (A, B), adult BalbC mouse (C, D) and rat (E, F). Abbreviations: Tal, talus; Cal, 
calcaneus; Cen & T3, fused central and tarsal bone III; Cen, central; T1, tarsal bone I; 
T2, tarsal bone II; T3, tarsal bone III; T4, tarsal bone IV; Met2, metatarsal II; Met5, 
metatarsal V. Scale bar = 0.5 mm.  
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Figure 4.5 Three-dimensional reconstructions for comparative anatomy of the left pes of 
the A) adult BalbC mouse (M. musculus), B) rat (R. norvegicus), and C) white-footed 
mouse (P. leucopus) in medial, cranial and lateral view from left to right. Abbreviations: 
Tib, tibia and fibula; Tal, talus; Ses, sesamoid; Cal, calcaneus; Med T, medial tibial; Cen 
& T3, fused central and tarsal bone III; Cen, central; T1, tarsal bone I; T2, tarsal bone II; 
T3, tarsal bone III; T4, tarsal bone IV; Met, metatarsals. Scale bar = A) 0.5 mm, B) 2.5 
mm, C) 1 mm. 
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Figure 4.6 Decalcified H&E stained histologic sagittal sections from a representative 
adult BalbC mouse (A & B) and adult Black6 mouse (C & D). Arrowheads designate 
hyaline cartilage within the fused central and tarsal bone III. Scale bars = 500 μm (A & 
C) and 100 μm (B & D).  
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published by Bab et al. (Bab et al., 2007). This study further characterizes these 
differences in two strains of mice by comparing the laboratory mouse morphotype to the 
closely related rat and the more distant white-footed mouse. Due to the fact that the 
observed tarsal fusion was not present in the rat, we believe this fusion to be a recent 
development due to extensive selective breeding of laboratory mice, potentially 
expediting evolutionary changes. In addition, histological evaluations showed the 
presence of hyaline cartilage in both laboratory strains, demonstrating that the central 
bone and tarsal bone III were likely, at one point, two separate bones. The presence of 
cartilage could indicate that either the bone has completely fused and this is the 
remnant of the joint space, or the bone has only partially fused, and the presence of the 
cartilage surrounded within bone is simply an orientation limitation of a two-dimensional 
view. It is possible that this fusion could have occurred during normal postnatal growth 
and development, as studies evaluating bone development show these bones as being 
separate in young mice (Storm et al., 1994, Patton and Kaufman, 1995); however, our 
findings are somewhat contradictory, as we identified this fusion in mice as young as 
three weeks old. One limitation to our study was that only one laboratory mouse at three 
weeks of age was analyzed. A potential explanation for these anatomical differences 
could be the different laboratory mouse populations. The laboratory mice used in this 
study were either purchased from the Jackson Laboratory or bred on site.  
 Several studies have characterized the fusion of the central and tarsal bone III as 
an abnormal finding secondary to mutations associated with brachypodism (Storm et 
al., 1994). Storm et al. (Storm et al., 1994) found fusion of the central and tarsal bone III 
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in BalbC mice with null mutations in GDF5 during embryonic development. It is thought 
that disrupting various members of the bone morphogenic proteins (BMPs) may affect 
differentiation and separation of precursor bones within the carpus and tarsus (Storm et 
al., 1994). In contrast, our data demonstrate that fusion of the central and tarsal bone III 
is likely a normal maturation characteristic, and not a pathological finding as described 
(Grüneberg and Lee, 1973, Storm et al., 1994). Furthermore, if this fusion in the tarsal 
bones occurred as the result of a genetic mutation within the inbred laboratory mouse 
strains, it is possible that this change occurred during the 20-50 years since those 
studies were published, meaning that the normal mice included in those studies did 
indeed have separated tarsal bones. More recently, Duce et al. (Duce et al., 2010) 
reported difficulties distinguishing the boundaries of the central and tarsal bone III using 
micro-magnetic resonance imaging of Black6 mice. These difficulties could be explained 
by our results. Our findings directly impact these studies, as we have shown that this 
fusion is not a lesion secondary to disease, and is in fact a normal occurrence within 
two laboratory mouse strains. 
 The central and tarsal bone III in the white-footed mouse are unfused and remain 
two distinctly separate bones. It is possible that fusion could occur in a later phase of 
maturation of the white-footed mouse; however, this does not appear to be the case, as 
the laboratory mice with a similar epiphyseal plate status show fused tarsal bones. In 
addition, tarsal bones ossify with a single center of ossification during development 
(Patton and Kaufman, 1995), thus normal postnatal fusion of these two bones is 
unlikely. Differences in the white-footed mouse and a laboratory mouse may be due to 
differences in locomotion (i.e., semi-saltatorial versus scansorial) or due to their distant 
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phylogenetic relationship. In addition, only two white-footed mice were available for 
evaluation. Future studies would require further and more comprehensive analyses of 
the tarsal anatomy of wild typed mice of various ages for direct comparisons to the 
skeletal anatomy of their distant inbred relatives. 
The absence of fusion in the closely-related rat shows that this fusion is specific 
to the laboratory mouse and is not an ancestral state. The fusion of the central bone 
and tarsal bone III is most likely the result of a genetic mutation from human-directed 
breeding; however, evaluations of a wild type M. musculus is necessary to determine if 
this fusion is only present in laboratory mice or also found in other populations. Although 
the mice used in this study are bred as control, wild type mice, they have still been 
subjected to inbreeding, and therefore may not reflect the true wild type state of mice. 
Herein we were able to successfully show that fusion of the central and tarsal 
bone III is a normal characteristic in adults of two strains of inbred laboratory mice 
commonly used for orthopedic research, as well as characterize the tarsal anatomy for 
the white-footed mouse and rat. Although we guardedly apply this conclusion to all 
strains and populations of laboratory mice due to sample size, we believe these findings 
should be considered for studies requiring detailed knowledge of tarsal anatomy in 
these species. It is possible that there are biomechanical consequences of the fusion of 
the central and tarsal bone III; however, the fusion does not span the entire distal 
intertarsal joint, and therefore only limits range of motion in the center of the joint. Joint 
fusions are common in horses with distal intertarsal osteoarthritis, and after surgical 
fusion, horses return to athletic performance without hindrance on range-of-motion in 
the tarsus (Dechant et al., 2005). Therefore, although the fusion of the central and tarsal 
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bone III may limit the overall movement of the joint, it likely does not have major 
consequences on gait. Clarification of the timing of fusion should be evaluated through 
the investigation of additional stages, including embryogenesis, as studies evaluating 
the effects of GDF 5/6 mutations in tarsal anatomy evaluate developmental anatomy. In 
addition, older mice (i.e., >1 year of age) should also be evaluated to determine if the 
cartilage and joint space observed disappears, indicating that fusion is actively 
occurring later in life.  
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CHAPTER 5.  
CONCLUDING REMARKS 
 
5.1 Overall Summary of Findings 
 The use of imaging in veterinary medicine has greatly advanced orthopedic 
research for both research and education purposes. This dissertation utilized one of 
these advanced imaging techniques, microCT, to analyze bone morphology in two 
animal models, answering several relevant questions in veterinary orthopedics: the 
effect of two FDA-approved bisphosphonate therapies (i.e. tiludronate and clodronate) 
on bone morphology and remodeling in horses, and the presence of tarsal variation in 
laboratory mice. In addition, this dissertation describes a novel, non-terminal bone 
biopsy method in the horse, providing the largest bone sample when compared to other 
methods previously described.  
 In Chapters 2 and 3, the aforementioned bone biopsy model was utilized to 
collect bone samples from the tuber coxarum of young, clinically healthy horses. Bone 
samples were analyzed via microCT and histomorphometry to determine the effect of 
clodronate and tiludronate on bone structure and remodeling. In addition, the effect of 
clodronate on bone healing after a bone defect was analyzed. We determined that 
tiludronate and clodronate, administered at the recommended dose, do not have an 
effect on bone morphology or bone remodeling after 60 days in young horses. However, 
tiludronate and clodronate may have preventing minor bony changes, as seen in the 
control group, from occurring in the treated horses. Additionally, clodronate does not 
appear to impact bone healing 60 days following creation of a defect.  
 In Chapter 4, we characterized the bony tarsal anatomy in two common strains of 
laboratory mice (i.e., Black6 and BalbC), and compared this anatomy to selected 
		97	
outgroups: the closely-related laboratory rat and the distantly related white-footed 
mouse. Utilizing microCT and histology, we confirmed that the central and tarsal bone III 
were fused in all laboratory mice evaluated. This fusion was not present in the rat or 
white-footed mouse. Histological sections showed the presence of hyaline cartilage 
surrounded by mature, trabecular bone. We conclude that although the bone is fused in 
these mice, a joint remnant remains.  
 
5.2 Significance of Research 
 Assessment of bone health through bone biopsies in many species, including 
horses, is typically accomplished through obtaining a core biopsy from the sternebrae, 
ribs, third metacarpal bone, fourth tarsal bone and tuber coxae (Misheff et al., 1992, 
Steiger et al., 1999, Désévaux et al., 2000, Delguste et al., 2011), which has been 
shown to have poor trabecular bone for histological evaluation (Steiger et al., 1999). 
The biopsy method described in this dissertation produced biopsies almost 9 times 
larger than previously described biopsy volumes from other locations (Savage et al., 
1991, Misheff et al., 1992, Steiger et al., 1999), with no associated morbidity or post-
surgical lameness. Additionally, we showed that the biopsy model proposed in the 
current studies allows one to obtain sequential biopsies, permitting evaluation of bone 
across several time points.   
 Currently, tiludronate and clodronate are used extensively in the veterinary 
clinical setting to treat abnormal bone remodeling diseases (Denoix et al., 2003), 
including to young horses (Carpenter, 2012), which are known to undergo more rapid 
bone remodeling than skeletally-mature adults (Goyal et al., 1981). Despite the wide 
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use of clodronate in the clinical setting, and it’s known systemic impact on the entire 
skeleton, there has been little to no research evaluating the effect of these drugs on 
normal bone remodeling in horses. Additionally, the effect of these drugs in young 
horses, who may be skeletally immature and undergoing increased bone remodeling 
and growth secondary to normal development, has not been evaluated. Our research 
shows that these drugs have minimal to no short-term effect on normal bone structure 
and remodeling in young horses. Additionally, we showed that in the presence of a bone 
defect, clodronate does not negatively affect normal bone remodeling after 60 days.  
 Rodent models are used for a variety of orthopedic research applications, 
including characterization of pathologic bony changes secondary to disease (Eulderink 
et al., 1998, Ford-Hutchinson et al., 2003, Goupil et al., 2016). Therefore, correct 
representations of normal bony anatomy are crucial in determining normal 
characteristics versus pathologic characteristics. Additionally, surgical procedures are 
guided by current knowledge of anatomy. Standard references for mouse anatomy 
show the mouse tarsus containing 8 individual bones (Cook, 1965), while a recent atlas 
of the mouse, utilizing microCT, demonstrated a fusion between two bones, and 
consisted of 7 individual bones (Bab et al., 2007). However, this atlas did not describe 
the fusion nor characterize it in relation to previous published anatomical descriptions of 
the tarsal region. Therefore, we were able to show that this fusion is present in two 
strains of wild-type laboratory mice. This fusion needs to be considered when studying 
diseases of the tarsus, or for surgical procedures involving the tarsus of mice.   
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5.3 Future Directions 
 The results presented in this dissertation show that tiludronate and clodronate do 
not affect bone structure and remodeling after 60 days. The next milestone of this 
project is to determine longer term effects of tiludronate and clodronate on bone, as well 
as increase sample size to determine if lesser effects exist. Additionally, due to their 
minimal effect shown in this study, the effect of tiludronate and clodronate on diseased 
bone in horses, specifically associated with navicular disease, needs to be evaluated as 
well, to determine the efficacy of these BPs.  
 We showed that fusion of the central and tarsal bone III is a normal characteristic 
in two strains of wild-type laboratory mice. Therefore, the next goal of this project is to 
evaluate additional individuals to increase sample size of the BalbC strain, as well as 
evaluate additional wild-type strains. Moreover, evaluating individuals from various 
mouse colony populations will help elucidate the extent of the fusion into all laboratory 
mice populations. Further evaluation of the anatomical extent of the fusion is also 
necessary, to determine if surrounding musculature and neurovasculature are affected. 
Finally, once affected mouse strains are known, determining genetic differences 
between mice with a fused bone versus mice without will facilitate researchers in 
determining the cause of the fusion, and possible interactions with future studies 
evaluating genetic manipulations or pathology. 
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APPENDICES 
 
Appendix A: First author, Colin F. Mitchell, provided permission for the second author to 
reuse material from article ‘Assessment of Tuber Coxae Bone Biopsy in the Standing 
Horse’.  
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Appendix B: Veterinary Surgery is a member of John Wiley and Sons, which provides 
reuse or repurposing of articles with permission.  
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Appendix C: Anatomical Record is a member of John Wiley and Sons, which provides 
reuse or repurposing of articles with permission.  
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